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ABSTRACT
ANALYSIS OF hMLHl GERMLINE MUTATIONS IN THREE TURKISH 
HEREDITARY NONPOLYPOSIS COLORECTAL CANCER KINDREDS
Cemaliye Akyerli
M.S. in Molecular Biology and Genetics 
Supervisor: Assist. Prof. Marie D. Ricciardone 
July 1998, 96 Pages
Hereditary nonpolyposis colorectal cancer (HNPCC) is one of the most 
common genetic diseases in Western world. It is a clinical syndrome characterized by 
an inherited predisposition to early onset colorectal and an increased incidence of 
other cancers. The disease is caused by a germline defect in one of five human DNA 
mismatch repair genes, hMLHl, hMSH2, hPMSl, hPMS2, and hMSH6. Defects in 
hMLHl and hMSH2 account for the majority of mutations found in HNPCC families. 
In this study, a variety of mutation detection methods were used to identify hMLHl 
germline mutations in three Turkish HNPCC kindreds.
Restriction enzyme analysis of genomic DNA was used to analyze five 
members of an HNPCC family with a previously described G884C mutation. The 
genotypes of all five individuals were determined by Dde\ digestion and the results 
were confirmed by DNA sequence analysis. Hph\ restriction enzyme analysis was 
used to analyze twenty-nine members of an unrelated HNPCC family for a previously 
identified A1652C mutation. Genotypes were determined for all individuals and the 
results were confirmed by DNA sequence analysis. Both of these restriction enzyme 
analyses are reliable, cost-effective methods that can be used in mutation screening 
programs for family members who request genetic counseling.
Single strand conformation polymorphism analysis (SSCP) was used to screen 
for unknown germline mutations. Nine DN A samples with defined mutations in the 
hMLHl gene were analyzed using several gel formulations and electrophoretic 
conditions to determine the most sensitive protocols. These protocols were then used 
for routine mutation detection.
In a third HNPCC family, for whom no mutation has yet been defined, the 
complete coding sequence of the hMLHl gene was screened by SSCP. Two exons, 7 
and 15, showed an altered mobility compared to control sequences. The nucleotide 
sequence of these two exons was determined by automated fluorescence DNA 
sequence analysis. The differential mobility observed for exon 15 appears to be due 
to an intonic polymorphism in the control sample. Preliminary results for exon 7 
show no difference between proband and control nucleotide sequences. Thus, the 
DNA mismatch repair defect in this kindred appears not to be in hMLHl. Further 
studies will focus on the analysis of hMSH2.
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ÖZET
KALITSAL POLİPOZ OLMAYAN KOLOREKTAL KANSERLİ ÜÇ TÜRK 
AİLESİNDE, hMLHl GENİNDEKİ EŞEY HÜCRESİ MUTASYONLARININ
ANALİZİ
Cemaliye Akyerli
Moleküler Biyoloji ve Genetik Yüksek Lisans 
Tez Yöneticisi: Yardımcı Doçent Dr. Marie D. Ricciardone 
Temmuz 1998, 96 Sayfa
Kalıtsal polipoz olmayan kolorektal kanseri. Batı ülkelerinde en sık rastlanan 
genetik hastalıklardan biridir. Bu klinik sendrom, erken yaşta ortaya çıkan kolorektal 
kanseri ve diğer kanserlerin ortaya çıkmasını artıran kalıtsal yatkınlıkla karakterizedir. 
Beş, insan yanlış eşleşme DNA tamir genlerinden (hMLHl, hMSH2, hPMSI, hPMS2, 
ve hMSH6) birinde olan eşey hücresi bozukluğu, bu hastalığın ortaya çıkmasına neden 
olur. Kalıtsal polipoz olmayan kolorektal kanserli ailelerde bulunan mutasyonlarm 
çoğunluğu, hMLHl ve hMSH2 genlerinde görülmektedir. Bu çalışmada, kalıtsal 
polipoz olmayan kolorektal kanserli üç Türk ailesinde bulunan eşey hücresi 
mutasyonlarının tanımlanması için çeşitli mutasyon tarama metodları kullanılmıştır.
Genomik DNA’nm restriksiyon enzim analizi, daha önceden tanımlanmış 
G884C mutasyonu taşıyan bir kalıtsal polipoz olmayan kolorektal kanserli ailenin beş 
ferdinin incelenmesinde kullanılmıştır. Bu beş bireyin genotipleri, Dde\ enzim analizi 
ile belirlenmiş ve sonuçlar DNA dizi analizi ile doğrulanmıştır. Daha önceden 
tanımlanmış A1652C mutasyonunu taşıyan diğer bir kalıtsal polipoz olmayan 
kolorektal kanserli ailenin yirmidokuz ferdi, Hph\ restriksiyon enzim analizi ile 
tanımlanmıştır ve sonuçlar DNA dizi analizi ile doğrulanmıştır. Her iki analiz de 
genetik danışma isteyen bu ailelerin mutasyon taramasında, güvenilir ve hesaplı 
tekniklerdir.
Tek iplikçikli yapısal çeşitlilik analizi, bilinmeyen eşey hücresi mutasyonlarının 
taranmasında kullanılmıştır. En hassas protokollerin belirlenmesi için, daha önceden 
mutasyonları tanımlanmış dokuz DNA örneği, çeşitli jel içeriği ve elektroforez 
koşullarında çalışılmıştır. Bu protokoller, daha sonra rutin mutasyon tarama 
çalışmalarında kullanılmıştır.
Mutasyonu henüz tanımlanmamış olan üçüncü bir kalıtsal polipoz olmayan 
kolorektal kanserli ailenin, hMLHl geninin bütün kodlayıcı dizisi, bu metodla 
taranmıştır. Ekson 7 ve 15, kontrol diziye göre farklılık göstermiştir. Bu iki eksonun 
nükleotid dizileri, floresan otomatik DNA analizi ile belirlenmiştir. Ekson 15 deki 
farklılığın, kontrol örnekteki intrönik bir polimorfızimden kaynaklandığı 
görülmektedir. Ekson 7 için ilk veriler, probanla kontrol nükleotid sekans arasında bir 
farklılık olmadığını göstermektedir. Sonuç olarak, bu ailedeki yanlış eşleşme DNA 
tamir bozukluğunun hMLHl geninden kaynaklanmadığı düşünülmektedir. İleriki 
çalışmalar, hMSH2 geninin incelenmesi üzerinde yoğunlaşacaktır.
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1. Introduction
1.1. Colorectal Cancer
Colorectal cancer is a significant cause of morbidity and mortality in Western 
populations. Approximately 50% of the Western population develops a colorectal 
tumor by age 70 and in approximately 10% of these individuals, the tumor will 
become malignant (Kinzler and Vogelstein, 1996). Colorectal cancer develops as a 
result of the pathologic transformation of normal colonic epithelium to an 
adenomatous polyp and ultimately an invasive cancer. This transformation is a 
multistep progression that requires years, possibly decades, and depends on a number 
of recently characterized genetic alterations.
Genetic alterations that confer a proliferative advantage on a specific cell and 
lead to cancer occur within three classes of genes: ( 1) proto-oncogenes, which when 
mutated (oncogenes), promote uncontrolled cell growth; (2) tumor suppresor genes, 
which when mutated, fail to regulate cell proliferation; and (3) DNA repair genes, 
which when mutated, fail to ensure fidelity of DNA replication, eventually leading to 
mutations in proto-oncogenes and tumor suppressor genes (Gryfe et al., 1997). 
Telomerase activity, which maintains the integrity of the chromosome ends and 
thereby immortalizes the cell, has been detected in almost all cancers, including 
colorectal cancer (Gryfe et al., 1997). Other genetic alterations that allow 
transformed colorectal epithelial cells to escape cell cycle arrest or apoptosis have also 
been recognized (Gryfe et al., 1997). In addition, hypomethylation or
hyperméthylation of DNA sequences may alter gene expression without nucleic acid 
mutation (Gryfe et al., 1997).
Epidemiologic studies strongly suggest that the diet can influence colorectal 
cancer incidence. Lipids are thought to be among the critical dietary components 
because a higher rate of colorectal cancer has been associated with diets containing 
large amounts of red meat. Moreover, it has been shown that nonsteroidal anti­
inflammatory drugs, that inhibit the cyclooxygenases that metabolize the lipid 
arachidonic acid, can prevent tumor formation and even cause existing colorectal 
tumors to regress (reviewed in Kinzler and Vogelstein., 1996).
Although most colorectal cancers are sporadic cancers that result from the 
accumulation of multiple genetic changes, some colorectal cancers have a hereditary 
genetic factor. The two most common familial colorectal cancers are familial 
adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal cancer 
(HNPCC).
l . l . l .  Familial Adenomatous Polyposis (FAP)
FAP is a rare, autosomal dominant inherited syndrome caused by germline 
mutations of the adenomatous polyposis coli (APC) tumor-suppressor gene located 
on chromosome 5q21-22. It is associated with almost complete penetrance and has 
an estimate germline frequency of 1 in 10,000 in the general population (Gryfe et al., 
1997). The disease is characterized by the development of hundreds to thousands of 
small benign polyps (adenomas) in the second or third decade of life. Left untreated, 
these polyps develop into large malignant cancers (carcinomas) at an average age of
44 years.
Patients with germline mutations of APC do not necessarily develop colorectal 
cancer but have a much greater risk compared to general population. Somatic 
inactivation of the wild-type APC allele is the first event and the rate-limiting step in 
FAP colorectal carcinogenesis. Mutation leading to deregulation of the K-/-av proto­
oncogene is also thought to be an early event in colon cancer formation. Loss of 
heterozygosity on chromosome 18q and consequent loss of tumor suppressor genes 
occurs later in the sequence of development from adenoma to carcinoma. Finally, 
mutation of the p53 tumor suppressor gene on chromosome 17p appears to be a late 
phenomenon in colorectal carcinogenesis, which probably allows the growing tumor 
with multiple genetic alterations to evade cell cycle arrest and apoptosis (reviewed in 
Kinzler and Vogelstein, 1996).
1.1.2. Hereditary Nonpolyposis Colorectal Cancer (HNPCC)
HNPCC is a relatively common autosomal dominant disease. It affects 1 in 
200 to 1,000 individuals and accounts for 3% of all colorectal cancers (Boland,
1998). HNPCC patients have an increased risk of colorectal cancer, that is 
distinguished from sporadic colorectal cancer by a younger age of onset (mid-40s). 
The risk of colorectal cancer in HNPCC individuals (penetrance) has been estimated 
at approximately 80% (Gryfe et al., 1997). In addition to colorectal cancers, HNPCC 
individuals have an increased incidence of other cancers, such as endometrium, ovaiy, 
stomach, small intestine, hepatobiliary system, kidney and ureter. Two subsets of 
families have been described; Lynch syndrome I families show only colorectal cancers 
and Lynch syndrome II families show tumors in other organs. Families with 
colorectal cancer are designated as HNPCC families if they fulfil the following criteria
defined by the International Collaborative Group on HNPCC (Amsterdam criteria):
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( 1) three or more relatives with histologically verified colorectal cancer, one of whom 
is a first-degree relative of the other two, (2) colorectal cancer affecting at least two 
generations, and (3) one or more colorectal cancer cases diagnosed before age 50 
(Lynch et al., 1993).
Cancers associated with HNPCC tend to have a high degree of genomic 
instability, which is manifested as alterations in the lengths of simple repeat elements 
or microsatellites (Ionov et al,, 1993; Thibodeau et al., 1993; Peltomaki et al., 1993b). 
This genomic instability is called microsatellite instability. A similar phenomenon had 
also been observed in bacteria and yeast with mutant DNA mismatch repair genes 
(Levinson and Gutman, 1987; Strand et al., 1993), These observations suggested that 
human homologs of the DNA mismatch repair genes might be involved in HNPCC.
To date, defects in five DNA mismatch repair genes have been linked to HNPCC: 
hMSH2 (Fishel et al., 1993; Leach et al., 1993), hMLHl (Lindblom et al., 1993; 
Bronner et al., 1994), hPMSl (Papadopoulos et al., 1994), hPMS2 (Nicolaides et al., 
1994) and hMSH6 (Akiyama et al., 1997). Because cancer develops in HNPCC when 
the DNA mismatch repair system fails, the gene products that function in eukaryotic 
mismatch repair are of great interest.
1.2. DNA Mismatch Repair
The term “mismatch repair” was initially coined to refer to a cellular activity
capable of recognizing abnormal base pairs and correcting the sequence on one strand
to restore a normal A»T or G*C pairing (Rhyu, 1996). This activity was also found
to correct stretches of unpaired bases that result from insertion or deletion of
nucleotides on one of the two DNA strands. Both prokaryotic and eukaryotic cells
are capable of repairing mismatched base pairs in their DNA.
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Mismatched base pairs in DNA can arise by several processes (Friedberg et 
al., 1995). A significant source of mismatched bases is DNA replication errors. 
Occasionally an incorrect nucleotide is incorporated into the DNA strand being 
synthesized. While the majority of these misincorporations are e.xcised by the DNA 
polymerase proofreading 3’-5’ exonuclease, approximately 1 in lO'^  errors remain. 
The DNA mismatch repair system can repair approximately 99.5% of the mutations 
that escape proofreading, thus, decreasing the error rate to 1 in lO'" base pairs 
(Boland, 1998). In this case, the correct base is located in the parental strand of the 
newly replicated DNA and correction of the mismatch helps maintain the fidelity of 
the genetic information.
Another source of mismatched base pairs is heteroduplex formation between 
two homologous, but slight different, DNA molecules during recombination. 
Mismatches can also result when hairpins form between imperfect palindromes. 
Mismatched base pairs can also arise when deamination of 5-methylcytosine converts 
a G*5-mC base pair to a G*T base pair. Finally mismatched base pairs result when 
base analogs or chemically modified derivatives of normal bases are incorporated into 
DNA.
DNA mismatch repair plays a major role in two cellular processes: ( I) repair 
of errors made during DNA replication or resulting from chemical damage to DNA 
and (2) processing of recombination intermediates that may yield new configurations 
of genetic markers. More recent studies have suggested that mismatch repair may 
also be crucial for: (3) regulation of recombination events between divergent DNA 
sequences that could result in different types of genetic instability, (4) nucleotide 
excision repair responsible for repair of physical/chemical damage to DNA and (5) 
participation in a cell cycle checkpoint control system by recognizing certain types of
DNA damage and triggering cell cycle arrest or other responses to DNA damage 
(reviewed in Kolodner, 1996).
1.2.1. DNA Mismatch Repair in Prokaryotes
The best understood DN A mismatch repair system is the methyl-directed 
mismatch repair system of lischcrichia coli, a system that has been completely 
reconstituted using purified enzymes (Lahue et al., 1989). Mismatch repair is tightly 
coupled with DNA replication, so that mismatches formed during DNA replication are 
repaired using the methylated parental strand as template, resulting in a reduction of 
misincorporation errors. The méthylation signals specifying the parental strand can be 
located a considerable distance from the actual mismatch and thus, the excision tracts 
associated with this pathway can be large, 10' bp or more, so the system is often 
referred to as long-patch DNA mismatch repair.
The A’, coli MutHLS system repairs a broad spectrum of mispaired bases. It 
recognizes and repairs all single-base mispairs except C*C (Kolodner, 1996). It also 
repairs small insertion / deletion mispairs, although it may not efficiently recognize 
insertion / deletion mispairs that have more than 4 unpaired bases. Strand 
discrimination is determined by recognition of N'’-methylation of the adenine residue 
in the GATC palindrome. Immediately after DNA replication, the newly-synthesized 
daughter-strand DNA is undermethylated relative to the parental strand. This 
difference in méthylation state between parental and daughter strands just behind the 
replication fork permits discrimination between the two strands.
Repair is initiated by binding of MutS protein to a mismatch. MutL 
subsequently binds to MutS and activates MutH, which then nicks the unmethylated
strand of DNA at hemimethylated GATC sites immediately 5’ to the guanine residue
6
(Figure 1). The incised strand is then displaced by DNA helicase II and excised from 
the nick to the mispaired base by one of the single-stranded DNA exonucleases 
(Exonuclease I [3’exonuclease activity]. Exonuclease VII [both 3’and 5’exonuclease 
activities] or Red exonuclease [5’exonuclease activity]) depending on whether the 
nicked is 5’ or 3’ to the mispair. Resynthesis of the DNA strand is mediated by DNA 
polymerase III, single-strand DNA-binding proteins and DNA ligase (reviewed in 
Kolodner, 1996, Eshleman et al., 1996).
MutL
5’
■MutH
Milts
Figure I. E. coii Mut HLS DNA mismatch repair system at replication fork.
Repair is initiated when MutS recognizes and binds the mismatch. Subsequently, 
MutL binds MutS and activates MutH, which then nicks the unmethylated strand of 
DNA at hemimethylated GATC sites. The unmethylated strand is then excised from 
the nick to the mispair. A new DNA strand is synthesized in the resulting gap. 
(Adapted from Kolodner, 1996.)
1.2.2. DNA Mismatch Repair in Eukaryotes
The overall mechanism of DN A mismatch repair has been highly conserved in 
evolution and eukaryotes have a mismatch repair system like the E. coli MutHLS 
system. In general, repair in eukaryotes involves heterodimeric protein complexes, 
rather than the single proteins or homodimers employed by bacteria (Lindahl et al., 
1997). However, the precise mechanisms of mismatch recognition, identification of 
the incorrect DNA strand, excision and replacement of the mismatched DNA segment 
is not yet well understood. As in prokai70tes, eukaryotic mismatch repair systems 
appear to play important roles in the maintenance of genetic fidelity during DNA 
replication, genetic recombination, and genome stability. In addition, they appear to 
be important for preventing the appearance of certain types of cancers.
1.2.2.1. DNA Mismatch Repair in Saccharomyces cerevisiae
In Saccharomyces cerevisiae, there are at least six proteins, Mshl-Msh6, 
which show a high degree of amino acid similarity with the bacterial MutS proteins 
(Kolodner, 1996). Three of these proteins, Msh2, Msh3 and Msh6, function in a 
eukaryotic MutHLS-like mismatch repair pathway. There are two different pathways 
of Msh2-dependent mismatch repair (Figure 2): one that is primarily specific for 
single-base substitution mispairs and requires a Msh2«Msh6 complex, and a second 
that is primarily specific for insertion / deletion mispairs and requires either a 
Msh2«Msh3 complex or a Msh2»Msh6 complex. The homologs of bacterial MutL 
protein in S. cerevisiae are Mlhl and Pmsl.
Single-base mispair recognition
Mlhl/Pmsl
Msh2 Msh6
Insertion-deletion mispair recognition
Mlhl/Pmsl Mlhl/Pmsl
Msh2 MsM
7 ^
Msh2
7 ^
Msh3
Figure 2. Model for mismatch recognition in S. cerevisiae.
Complexes between Msh2 and either Msh3 or Msh6 interact with a single base 
substitution mispair or an insertion / deletion mispair. Exactly which protein - Msh2, 
Msh3 or Msh6 - actually interacts with the mispaired base is not known. The 
MlhUPmsl complex interacts with the mispair recognition complex. (Adapted from 
Kolodner, 1996.)
1.2.2.2. DNA Mismatch Repair in Human Cells
The initial steps of correction can be classed as primary and secondary 
recognition events (Lindahl et al., 1997). Primary recognition and binding of 
mismatched DNA (Figure 3) is carried out by homologs of the E. coli MutS protein, 
hMSH2, hMSH6 (GTBP) and hMSH3, which can associate to form two different 
heterodimers. The hMutSa heterodimer contains hMSH2»hMSH6 and recognizes 
single base mispairs, single base loops and two base loops in repeated dinucleotide 
sequences. The hMutSP heterodimer contains hMSH2»hMSH3 and preferentially 
binds two, three and four base loops.
The secondary recognition event involves the hMutLa heterodimer, which is 
composed of two homologs of the E. coli MutL protein, hMLHl*hPMS2. The
hMutLa heterodimer binds both the hMutSa-DNA and hMutSp-DNA complexes 
(Figure 3). Cells with inactivating mutations in either of these components are 
completely mismatch repair-deficient. Addition of the hMutLa heterodimer to these 
defective cell extracts is sufficient to restore mismatch repair activity (Lindahl et al., 
1997). Following mismatch recognition, the DNA strand with the incorrect base is 
excised and a new DNA strand is synthesized by DNA polymerase using the 
nonmutated strand as a template. Finally, DNA ligase seals the gaps and completes 
repair.
Eukaryotic cells lack d(GATC) méthylation and, accordingly, no eukaryotic 
homologue to the MutH endonuclease MutH has been identified. Some other method 
of distinguishing the strands presumably exists. One hypothesis is that strand gaps 
between the Okazaki fragments on the daughter strand may direct the strand 
specificity of mismatch repair (Boland, 1998). Recently the DNA replication protein 
proliferating cell nuclear antigen (PCNA) was found to associate with hMLHl and 
hMSH2 and participate in an early step of mismatch repair (possibly in strand 
discrimination) (Umar et al., 1996). PCNA also interacts with the exonuclease 
complex DNase IV/FEN1 and may stimulate nicking to facilitate removal of the 
mismatched DNA segment (Chen et al., 1996). Thus, PCNA may have multiple roles 
in mismatch repair.
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Primary recognition
a.
G T GT GT GTC GTAC
b. Secondaiy recognition
liMutLa
Removal and restoration
C.
G
T
T · 
A-
GT ■ 
CA-
GT-
CA-
GTC-
GAG-
GTAC · 
CATG
Figure 3. Early steps in human DNA mismatch repair.
a. Primary recognition: the heterodimer hMutSa (hMSH2«hMSH6) preferentially 
recognizes single base mispairs, single base loops, and two base loops in repeated 
dinucleotide sequences, while the heterodimer hMutSP (hMSH2»hMSH3) 
preferentially binds two, three and four base loops, b. Secondary recognition: the 
MutLa heterodimer is recruited by the hMutSa-DNA and hMutSP-DNA complexes. 
The stretch of DNA containing the mismatch is excised, resynthesized and ligated to 
complete repair. (Adapted from Lindahl et al., 1997.)
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1.3. Microsatellite Instability in HNPCC
Microsatellite loci are short units (one to five base pairs) of DNA that are 
tandemly repeated. The repeat nature of microsatellites makes these DNA sequences 
particularly prone to mutation due to unequal crossing-over during genetic 
recombination and/or slippage of DNA polymerase during DNA replication (reviewed 
in Friedberg et al., 1995). During genetic recombination events, if the DNA repeat 
sequences misalign, the resulting recombinants will have different lengths. During 
DNA replication, the primer and template DNA strands can transiently disassociate 
and the realign in a different configuration. If the unpaired bases are in the primer 
strand, continued synthesis results in an insertion event and elongation of the 
microsatellite. If the unpaired bases are in the template strand, continued synthesis 
results in a deletion event and shortening of the microsatellite. When the DNA 
mismatch repair system is intact, these errors are usually repaired so genome stability 
is maintained.
Researchers working with E. coli showed that defects in mutS and mulL 
increased the frequency of frameshift mutations in poly (GT)n tandem repeats about 
13-fold (Levinson and Gutman, 1987). In a similar manner, researchers studing 
eukaryotic mismatch repair in S. cerevisiae demonstrated that mutations in Pmsl, 
Mlhl and Msh2 caused a 100-700-fold increase in (GT)n tract instability (Strand et 
al., 1993). On the basis of these observations, researchers concluded that an intact 
DNA mismatch repair system was important for the stability of these short repeat 
sequences.
In 1993 three research groups looking for loss of heterozygosity in colorectal
tumors found an unusual somatic mutation — the insertion/deletion of simple repeat
elements or microsatellites -  in 12-15% of colorectal tumors (Ionov et al., 1993,
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Thibodeau et al., 1993; Peltomaki et al., 1993b). Hundreds of thousands of 
microsatellites are present throughout the human genome, usually in intronic regions 
of DNA. Multiple alleles with varying numbers of repeat units exist and the loci are 
highly polymorphic within the population. For each microsatellite locus, individuals 
have two alleles, often with different numbers of repeat units. Microsatellite lengths 
are the same within an individual's normal tissues. The observance of widespread 
variation in microsatellite lengths in HNPCC tumors was termed replication error 
(RER) phenotype or microsatellite instability (Ml).
1.4. Identification of Human DNA Mismatch Repair Genes
Based on these observations of microsatellite instability in HNPCC tumors and 
previous observations in bacteria and yeast, it was predicted that the HNPCC defect 
would be a mutation in one of the mismatch repair genes (Aaltonen et al., 1993). 
Linkage analysis of several large HNPCC families showed that the disease was linked 
to chromosomes 2 (Peltomaki et al., 1993a) and 3 (Lindblom et al., 1993).
1.4.1. Human Homologs of MutS
The first HNPCC gene hMSH2 was identified using both the candidate gene
approach (Fishel et al., 1993) and positional cloning (Leach et al., 1993). Fishel et al.
(1993) used degenerate PCR primers designed on amino acid sequences conserved
between bacteria and yeast to ampliiy MutS homologs from colon cancer cell lines.
PCR products of expected size were identified, cloned, sequenced and shown to
encode a predicted amino acid sequence with homology to MutS. Physical mapping
localized the HMSH2 gene to chromosome 2. Leach et al. (1993) used polymorphic
markers to define a 0.8-Mb interval containing the HNPCC locus. They then showed
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that a MutS homolog mapped within this interval. Both groups demonstrated the 
existence of germline mutations that altered the predicted protein product and 
cosegregated with the disease in HNPCC families.
1.4.2. Human Homoigs of IVIutL
After the human homologs of mutS gene of bacteria and yeast were found to 
have mutations for HNPCC, investigators searched for other human mismatch repair 
genes. Two groups simultaneously reported the cloning of the human MutL 
homolog, hMLHI (Papadopoulos et al., 1994; Bronner et al., 1994). Papadopoulos 
et al. (1994) surveyed a larged database of expressed sequence tags (ESTs) and found 
3 human mismatch repair genes related to the bacterial MutL gene. One gene, 
hMLHI, was mapped to chromosome 3p21.3 by fluorescence in situ hybridization. 
The other two genes were more similar to the yeast mutL homolog, PMS1, and were 
therefore denoted hPMSI and hPMS2. Bronner et al. (1994) used degenerate PCR 
primers designed on amino acid sequences conserved between bacteria and yeast to 
isolate a human MutL homolog that also mapped to chromosome 3p. Deleterious 
hMLHl germline mutations were demonstrated to cosegregate with disease in 
HNPCC families (Papadopoulos et al., 1994; Bronner et al., 1994).
1.4.3. Homology Alignment of DNA IMismatch Repair Genes
Homology alignment of the E. coli mutL (SwissProt: P23367), S. cerevisiae 
MLHl (SwissProt: P38920) and human MLHl proteins (SwissProt: P40692) was 
performed using the Multiple Sequence Alignment program
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(http://www.ibc.wustl.edu./ibc/msa.html). As seen in Figure 4, the amino terminal 
sequences of the proteins have the highest homology. The human and yeast MLH1 
proteins show 41% identity.
The same alignment program was used to align E. coli mutS (SwissProt: 
U29579), S. cerevisiae MSH2 (SwissProt: M84170) and human MSH2 proteins 
(SwissProt: P43246). As seen in Figure 5, the carboxy-terminal sequences have the 
highest homology.
In Figure 4 and Figure 5, the identical amino acids are green shaded and 
similar amino acids are yellow shaded.
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Figure 4. Homology alignment of MutL faomologs.
Alignment was performed using the Multiple Sequence Alignment program (http;//www.ibc.wustl.edu. 
/ibc/msa.html). Row 1: human MLHl sequence (SwissProt: P40692); Row 2: S. cerevisiae MLHl 
sequence (SwissProt: P38920); Row 3; E. coli mutL sequence (SwissProt: P23367).
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Figure S. Homology alignment of MutS homologs.
Homology alignment was performed using the Multiple Sequence Alignment program (http://www.ibc. 
wustl.edu./ibc/msa.html). Row 1: human MSH2 sequence (SwissProt: P43246); Row 2: S. cerevisiae 
MSH2 sequence (SwissProt: M84170); Row 3: E. colt mutS sequence (SwissProt: U29579).
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1.5. DNA Mismatch Repair Gene Defects in HNPCC
Germline mutations have been identified in five of the six mismatch repair 
genes believed to play a role in DNA mismatch repair in humans (Table 1): hMSH2 
(Fishel et al., 1993; Leach et al., 1993), hMLHI (Papadopoulos et al., 1994; Bronner 
et al., 1994), hPSM2 (Nicolaides et al., 1995), hPMSI (Nicolaides et al., 1995) and 
HMSH6 (Akiyama et al., 1997). Mutations in hMSH2 and hMLH 1 account for the 
majority of HNPCC kindreds, while mutations in hPMS2, hPMSi and liMSH6 are 
rare (Papadopoulos and Lindblom, 1997).
Table 1: DNA Mismatch Repair Genes Implicated in HNPCC
H. sapiens Chromosome E. coli Mutation
Gene Location Homolog Frequency“’’’·'
hMSH2 2pl6 Muts 38
hMSH3 5q Muts
_________________
0
hMSH6 2pl6 Muts 1.5
hMLHI 3p21 MutL 59
hPMSI 2q31 MutL 0.5
hPMS2 7p22 MutL 1.0
“Human Gene Mutation Database hltp://vvw'\v.uweni.ac.uk/uwcni/mg/ 
''International Coll. Group on HNPCC http://wvvw.nfdlit.nl/dalabase/nilhl/hlm 
"'Papadopoulos and Lindblom. 1997 
Total number of different mutations (n) = 224.
1.5.1. Location of Mutations in hMLHI and hMSH2
The hMLHI gene covers approximately 58 kb of genomic DNA, contains 19 
exons and codes for 756 amino acids (2268 bp). Mutations in hMLHI are dispersed 
throughout the coding region (Table 2). Two mutations, common in the Finnish 
population, are due to founder effects (Nystrom-Lahti et al., 1995). One, a 3.5 kb
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genomic deletion that results in deletion of exon 16, was detected in thirty-four 
Finnish families. The other, a G—>T transversion in the splice acceptor of exon 6 that 
results in truncation of the protein, was detected in ten Finnish families. There 
appears to be one potential hotspot for mutations in exon 16, where an A AG (Lys) 
deletion was observed in eleven families worldwide.
The hMSH2 gene covers approximately 73 kb of genomic DNA, contains 16 
exons and codes for 934 amino acids (2802 bp). Mutations in HMSH2 are also 
dispersed throughout the coding region with the exception of two potential hotspots. 
The first hotspot is the splice donor site for exon 5, where a, A->T transition 
mutation causes and inframe deletion of exon 5; this mutation has been detected in 22 
families worldwide. The second hotspot is in exon 12, where an AAT (Asn) deletion 
has been reported in eight families worldwide.
1.5.2. Types of Mutations in liMLHJ and hMSH2
The types of mutations reported for hMLHl (Table 4) and hMSH2 (Table 5) 
are also heterogeneous and includes missense mutations, nonsense mutations, splicing 
mutations, small insertions and small deletions. The majority of mutations reported 
for both hMLHl and HMSH2 result in truncation of the protein product (67% and 
80%, respectively). The predominant type of mutations for hMLHl was single base 
substitutions (65%). Mutations in hMSH2 resulted both from single base 
substitutions (45%) and small insertions/deletions (55%).
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Table 2: h M L H l  Mutation Frequency
Exon No. of Mutations Frequency (%)
1 12 5.2
2 11 4.8
3 4 1.7
4 8 3.5
5 1.3
6 11 4.8
7 1.3
8 11 4.8
9 11 4.8
10 7 3.0
11 11 4.8
12 10 4.3
13 12 5.2
14 13 5.7
15 5 2.2
16 63 27.4
17 13 5.7
18 5 2.2
19 17 7.4
Total 230 100
The Human Gene Mutation Database http:/A\'vvw.uwcni.ac.uk/uwcm/nig/ 
'’International Coll. Group on HNPCC htlp://www.nfdht.nl/database/mlhl/htm 
'’Papadopoulos and Lindblom, 1997
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Table 3: /tMV//2 Mutation Frequency
Exon No. of Mutations “ Frequency (%)
1 J 2.4
2 3 2.4
3 8 6.4
4 2 1.6
5 26 20.8
6 7 5.6
7 12 9.6
8 8 6.4
9 2 1.6
10 7 5.6
11 5 4.0
12 25 20.0
13 6 4.8
14 3 2.4
15 6 4.8
16 2 1.6
Total 125 100
T he Human Gene Mulalion Database hllp://mv\v.uwcm. ac.uk/uwcm/mg/ 
‘’International Coll. Group on HNPCC http://w'ww.nfdht.nl/database/msh2/htm 
‘’Papadopoulos and Lindblom. 1997
Table 4: Mutation types in hM L H l
Mutation Type Number of Mutations
Nucleotide substitution (missense) 44
Nucleotide substitution (nonsense) 15
Nucleotide substitution (splicing) 27
Small deletion 25
Small insertion 18
Small insertion / deletion 2
Complex rearrangement 2
Total 133
Table 5: Mutation types in tiMSH2
Mutation Type Number of Mutations
Nucleotide substitution (missense) 17
Nucleotide substitution (nonsense) 16
Nucleotide substitution (splicing) 5
Small deletion 38
Small insertion 8
Gross insertion / duplication 1
Total 85
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1.6. Mouse Models for HNPCC
Mice canying disruptions in DNA mismatch repair genes can provide insights 
into HNPCX' tumorigenesis. Knock-out mice ioxMlhl and Msh2 are viable but they 
show a high degree of genomic instability (de Wind et al., 1995; Reitmair et al„
1995). By one year of age, the majority of the knock-out mice have developed 
lymphomas, intestinal adenomas and adenocarcinomas (Baker et al., 1996; Prolla et 
al., 1998; Reitmair et al., 1996). Both male and female mismatch repair-deficient mice 
are sterile (Bedell et al., 1997). Male M//7/-deficient mice are infertile because their 
spermatocytes fail to progress beyond pachytene stage of meiosis (Baker et al., 1996; 
Edelmann et al., 1996). Further studies with these animal models may help define the 
role of DNA mismatch repair genes in cancer susceptibility.
1.7. HNPCC Tuinorigenesis
Development of both sporadic and inherited colorectal cancer is a multistep 
process that requires several genetic changes. Hereditary colorectal cancers develop 
at a much younger age than sporadic colorectal cancers because these indivdiuals are 
born with germline mutation that predisposes to cancer development (Tannergard et 
al., 1997). The germline defect in HNPCC individuals is a germline mutation in one 
of the genes involved in DNA mismatch repair. Heterozygous individuals have 
apparently normal DNA mismatch repair activity (Tannergard et al., 1997). However, 
somatic mutation of the wild-type allele results in loss of this ability and accumulation 
of characteristic mutations, such as single base mispairs and length alterations in 
homopolymeric tracts (Hemminki et al., 1994).
Kinzler and Vogelstein (1997) have classified genes involved in tumorigenesis
as either gatekeepers or caretakers. Cell cycle regulatory genes are termed
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gatekeepers because mutational inactivation of these genes results in the initiation of 
tumorigenesis. DNA mismatch repair genes are termed caretakers because they 
protect the integrity of the genome. One of the first manifestations of defective DNA 
mismatch repair is the characteristic microsatellite instability that is seen in HNPCC 
tumors. (Herfarth et al., 1997). Microsatellite instability can result from mutations in 
any of the genes required for mismatch repair (Boyer et al., 1995). This microsatellite 
instability is one sign of the genome-wide instability or “mutator phenotype” (Loeb, 
1991; Parsons et al., 1993) that accelerates tumor progression.
hMLHl and hMSH2 proteins are localized in the nucleus and are highly 
expressed in the epithelium of the digestive tract (Fink et al., 1997). However, 
mismatch repair genes are believed to be expressed in all proliferating cells (de Wind 
et al., 1998). Therefore, it is surprising that HNPCC tumorigenesis occurs 
predominantly in the colon. This tissue specificity can be explained in several ways 
(de Wind et al., 1998): (1) oncogenic mutations in mismatch repair-deficient cells 
may accumulate more rapidly in tissues with a high cell turnover and in tissues 
exposed to mutagens; (2) proto-oncogenes or tumor suppressor genes that control 
growth and differentiation of susceptible tissues may have mononucleotide tracts that 
are hot spots for mutations in mismatch repair-deficient cells, and (3) mismatch 
repair-deficient cells may have a growth advantage with respect to mismatch repair- 
proficient cells . In fact, tumors isolated from HNPCC individuals have been found to 
have mutations in mononucleotide tracts within several growth regulating genes, 
including the transforming growth factor-β type 11 receptor ( Ί'ϋΙ'βΚΙΓ) (Markowitz et 
al., 1995), the insulin-like growth factor type 11 receptor (IGMIR) (Souza et al.,
1996), and BAX (Rampino et al., 1997).
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Individuals from families at high risk for colorectal cancer should be offered 
genetic counseling, predictive molecular testing and, when indicated, endoscopic 
surveillance at appropriate intervals. Early detection of mutations in these tumor 
susceptibility genes would allow more effective monitoring of individuals at risk.
1.8. IMutatioii Screening
Because the hMLHl and hMSH2 are long genes (58 kb and 73 kb, 
respectively) with many exons (19 and 16, respectively), it is very difficult to detect 
mutations. Detection of unknown mutations can involve DNA sequences analysis of 
thousands of bases and would require large amounts of money and time. This has 
lead to the development of many techniques that can be used in research and clinical 
laboratories to screen populations for unknown mutations, as well as to detect known 
mutations.
An optimal mutation detection technique would ( 1 ) be fast, (2) be able to 
screen large stretches of DNA with high sensitivity and specificity, (3) not involve 
expensive or elaborate instrumentation, (4) not require toxic or dangerous compounds 
and (5) provide information about the location and nature of the mutation. 
Unfortunately, no single procedure yet described possesses all of these attributes.
1.8.1. Protein Truncation Test
The protein truncation test (PTT) rapidly detects mutations that interrupt the 
reading frames of genes. Templates are generated by PCR using cDNA synthesized 
by reverse transcription of mRNA (RT-PCR). A promoter is incorporated into 
forward primer. After in vitro transcription and translation assays are performed, the
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protein product is analyzed by gel electrophoresis. If there is a truncating mutation, 
the protein will have lower molecular weight compared to the normal protein.
1.8.2. RT-PCR
mRNA is isolated from blood and RT-PCR is performed by using exonic 
primers. After that, the products are analyzed on the gel. If there is a mutation, the 
size of PCR product may be smaller or the PCR product may not be detected if there 
is no mRNA transcript. This method is very useful for detecting exonic deletions that 
might not be detected using genomic DNA.
1.8.3. Heteroduplex Analysis (HA)
Complementary single-stranded DNA derived from alleles that differ in 
sequence will include mismatched base pairs (heteroduplexes) when allowed to 
anneal. Heteroduplex molecules are formed by denaturing DNA at 95‘’C and then 
allowing the single stands to anneal by cooling to room temperature slowly. Double- 
stranded heteroduplex molecules may show an altered electrophoretic migration in 
non-denaturing gels compared to homoduplexes of either allele. The main advantage 
of HA is its simplicity, but its sensitivity is about 80-90% (Grompe, 1993).
1.8.4. Single-Strand Conformation Polymorphism Analysis (SSCP)
The SSCP method relies on the fact that single-strand DNA molecules in 
solution under certain conditions have a defined secondary structure. In principle, 
when a single-stranded DNA molecule is placed in a non-denaturing solution, it will 
fold in a sequence specific manner. If one of the bases is changed, the molecule is
likely to fold into a different shape and size. During non-denaturing gel
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electrophoresis, the diflferent shaped molecules are likely to move at different rates so 
that when electrophoresis is stopped, their positions will be different. This differential 
mobility can allow one to distinguish normal and mutant alleles. Because there are 
two complementary mutant strands, each mutant allele has two chances of beina 
detected.
The most clear advantage of SSCP is the simplicity of the method. It can be 
done without labeling. The mutation detection rate depends on the length of the 
fragments. As the length of fragments increase, the sensitivity decreases. SSCP is 
sensitive only for 200-300 bp fragments and mutation detection rate is 80-90%. 
Variation of gel concentration, gel composition, and/or electrophoresis parameters 
may improve resolution and increase the mutation detection rate.
1.8.5. DNA Sequence Analysis
DNA sequencing refers to direct determination of the nucleotide sequence of a 
DNA fragment. Because DNA sequencing defines both the location and the nature of 
the change, it is the confirmatory step of any mutation screening method.
Two sequencing methods are used: the Maxam-Gilbert chemical cleavage 
method and the Sanger dideoxy chain termination method. In the Maxam-Gilbert 
method, a segment of DNA is labeled at one end and the phoshodiester bonds 
between specific bases are cleaved by using specific chemicals. This generates a series 
of labeled fragments, the lengths of which depend on the distance of the destroyed 
base from the labeled end of the molecule. The sets of labeled fragments are run side 
by side on an polyacrylamide gel that separates DNA fragments according to size and 
the gel is autoradiographed. The pattern of bands on the X-ray film is analyzed to
determine the nucleotide sequence.
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In the Sanger method, the DNA strand to be sequenced along with a labeled 
primer, is divided into four DNA polymerase reactions, each containing one of four 
dideoxynucleotriphosphates (ddNTPs). Incorporation of a dideoxynucleotide 
terminates DNA synthesis of that molecule. The concentration of the reactants is 
adjusted to allow some chain termination to occur at each base. The resultant labeled 
fragments are then separated by size by electrophoresis in a denaturing polyacrylamide 
gel. After autoradiography, the nucleotide sequence is determined by the pattern of 
the bands.
Automated sequencing relies on incorporation of fluorescent molecules during 
DNA extension reactions. Fluorescent dye labels can be incorporated using either 5’- 
dye labeled primers (dye primers) or 3’-labeled dideoxynucleotide triphosphates 
(ddNTPs) (dye terminators). With dye terminator labeling, each of the four ddNTPs 
is tagged with a different fluorescent dye. Thus, the growing chain is simultaneously 
terminated and labeled with dye that corresponds to that base.
During electrophoresis, the DNA bands are excited by a laser light as they 
migrate past a set point in the gel. Each dye emits light at a different wavelength. 
Therefore, all four colors can be detected and distinguished in a single gel lane. The 
data is collected and analyzed by sophisticated software. This strategy improves 
sequencing accuracy because it eliminates problems caused by variations in 
electrophoretic mobility from lane to lane. It also increases the number of templates 
that can be analyzed on a single gel. However, despite improvements in sequencing 
chemistry and in the software for heterozygote detection, direct automated 
sequencing of PCR products does not guarantee complete mutation detection and 
requires time-consuming and costly optimizations.
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1.8.6. Restriction Enzyme Analysis
Restriction endonucleases recognize short DNA sequences and cleave double 
stranded DNA at specific sites within or adjacent to the recognition sequences. The 
recognition sequences are generally, but not always, 4 to 6 nucleotides in length and 
are usually characterized by palindromic sequences. In palindromic sequences the 
recognition site sequence is the same on each DNA strand when read 5’^ 3 ’. Some 
l estriction enzymes cleave at the axis of symmetry yielding “blunt” ends. Others make 
staggered cleavages yielding “sticky” ends. Restriction enzyme cleavage is 
accomplished by incubating the enzyme with the DNA in appropriate reaction 
conditions. The amounts of enzyme and DNA, the buffer and ionic concentrations, 
and the temperature and duration of reaction vary depending upon the specific 
application.
1.9. Aim and Strategy
This project aims to detect germline mutations in the DNA mismatch repair 
gene, hh4LHI, in Turkish patients with hereditary non-polyposis colorectal cancer. 
hMLHI is the gene most frequently mutated in HNPCC. SSCP will be used for 
detection of unknown gene mutations. Restriction enzyme analysis will be used for 
detection of known gene mutations that occur in the enzyme recognition site. 
Automated sequencing will be used for confirmation of results. Identification of the 
germline mutations in Turkish individuals may provide insights into the kinds of 
disease mutations in the Turkish population. This might allow a reliable and cost- 
effective screening procedure to be used to identify individuals at high risk of 
developing colorectal cancer. These individuals could then be closely monitored to
detect tumors at an early stage when treatment is most effective.
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2. Materials and Methods
2.1. Materials
2.1.1. Patient samples
HNPCC patients were rei'en ed to Bilkent University, Faculty of Science, 
Molecular Biology Department (Ankara, Turkey) by collaborating physicians at 
Marmara University (Istanbul, Turkey), Hacettepe University (Ankara, Turkey), 
Akdeniz University (Antalya, Turkey) and Çukurova University (Adana, Turkey). 
Blood samples were collected in tubes containing EDTA. HNPCC family pedigrees 
are shown in Figures 6-10.
2.1.2. Cell Lines
Four lymphoblastoid cell lines with defined mutations in hMLHl were 
provided by M. Öztürk from I ARC, Lyon, France.
2.1.3. Oligonucleotides
Primers used in polymerase chain reactions and cycle sequencing reactions 
were synthesized on the Beckman Oligo lOOOM DNA synthesizer (Beckman 
Instruments Inc., Fullerton, CA, USA) at Bilkent University, Faculty of Science, 
Department of Molecular Biology and Genetics (Ankara, Turkey). The nucleotide 
sequences of the primers used for the analysis of the hMI.HI gene are given in Table 
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Table 6: Sequences of hM LHI  primers
Exons Name Sequence (5'->3')
MLHOl F GA281 CACTGAGGTGATTGGCTGAA
MLHOl R GA282 CCGTTAAGTCGTAGCCCTTA
MLH02 F GA 283 GTAC ATTAG AGTAGTTGC AGAC
MLH02 R GA284 CAGAGAAAGGTCCTGACTC
MLH03 F GA 152 GAGATTTGGAAAATGAGTAAC
MLH03 R GA 153 ACTAACAAATGACAGACAATG
MLH04 F GA 285 CTTTCCCTTTGGTGAGGTGA
MLH04 R GA286 TACTCTGAGACCTAGGCCCA
MLH05 F GA 156 CCCTTGGGATTAGTATCTAT
MLH05 R GA 157 TACTCTCCCATGTACCATTC
MLH06 F GA 287 GGGTTTTATTTTCAAGTACTTCTATG
MLH06 R GA288 CAGCAACTGTTCAATGTATGAGCAC
MLH07 F GA 289 GTGTGTGTTTTTGGCAACTC
MLH07 R GA 290 CCTTATCTCCACCAGCAAAC
MLH08 F GA 291 CTCAGCCATGAGACAATAAATCC
MLH08 R GA 292 GGTTCCCAAATAATGTGATGG
MLH09 F GA 164 TGGATGGATGAATGGACAGG
MLH09 R GA 165 GGATTTCCAATGTGGTTCTT
MLHIO F GA333 TGAATGTACACCTGTGACCTCACC
MEHI O R GA 334 GAGGAGAGCCTGATAGAACATCTG
MLHl 1 F GA337 CTTTTTCTCCCCCTCCCACTA
MLHll R GA338 TCTGGGCTCTCACGTCT
MLH12 F GA 339 AATTATACCTCATACTAGC
MLHI2R GA340 GTTTTATTACAGAATAAAGGAGG
MLH13 F GA 343 TGCAACCCACAAAATTTGGC
MLH13 R GA 344 CTTTCTCCATTTCCAAAACC
MLH14F GA 293 TGGTGTCTCTAGTTCTGG
MLH14R GA294 CATTGTTGTAGTAGCfCTGC
MLHI5 F GA 172 TGTCTCATCCATGTGTCAGG
MLH15 R GA 173 GCGGTCAGTTGAAATGTCAG
MLHr6 F GA 345 CATTTGGATGCTCCGTTAAAGC
MLH16R GA 346 CACCCGGCTGGAAATTTTATTTG
MLH17F GA 176 GAAAGGCACfGGAGAAATGG
MLH17R GA 177 ccgaaatgcttagt 'atctgc
MLH18 F GA 178 AAGTAGTCTGTGATCTCCGT
MLHi s R GA 179 AAGATGTATGAGGTCCTGfc
MLH r9 F GA 180 CAGGACACCAGTGTAtGTfG
MLH l9 R GA 181 AAGAACACATCCCACAGTGC
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The chemicals and reagents used in this study were purchased from the 
following suppliers:
2.1.4. Chemicals and Reagents
Reagent
Acrylamide 
Acetic acid 
Agarose
Ammonium persulfate 
Bisacrylamide 
Blue dextran 
Boric acid 
Bromophenol blue 
Cellulose acetate filters 
Chloroform
Disodium ethylenediamine tetraacetate 
Ethanol
Ethidium bromide 
Ficoll Type 400 
Formamide 
Glycerol 
Isoamyl alcohol 
MDE gel solution 
NuSieve 3:1 Agarose 
Silver nitrate 
Phenol 
Proteinase K
QIAquick PCR purification kit 
Sodium acetate 
Sodium chloride 
Sodium dodecyl sulfate (SDS)
Sodium hydroxide 
TEMED 
Tris HCl 
frisodium citrate 
Urea
Xylene cyanol
<j)xl74 HaelW DNA Marker (0,5 mg/ml) 
(j)x 174 HinfL DNA Marker (0,5 mg/ml) 
^^P-dCTP (10 MBq/0,025 ml)
” P-dATP (10 mCi/ml)
Supplier
Sigma, St. Louis, MO, USA
Carlo Erba, Milano, Italy
Sigma, St. Louis, MO, USA
Sigma, St. Louis, MO, USA
Sigma, St. Louis, MO, USA
Sigma, St. Louis, MO, USA
Sigma, St. Louis, MO, USA
Sigma, St. Louis, MO, USA
Costar, Cambridge, MA, England
Carlo Erba, Milano, Italy
Carlo Erba, Milano, Italy
Merck, Frankfurt, Germany
Sigma, St. Louis, MO, USA
Sigma, St. Louis, MO, USA
Sigma, St. Louis, MO, USA
Carlo Erba, Milano, Italy
Carlo Erba, Milano, Italy
FMC BioProducts, Rockland, ME, USA
FMC BioProducts, Rockland, ME, USA
Sigma, St. Louis, MO, USA
Carlo Erba, Milano, Italy
Appligene-Oncor, USA
Qiagen, Chatsworth, CA, USA
Carlo Erba, Milano, Italy
Sigma, St. Louis, MO, USA
Sigma, St. Louis, MO, USA
Sigma, St. Louis, MO, USA
Carlo Erba, Milano, Italy
Sigma, St. Louis, MO, USA
Sigma, St. Louis, MO, USA
BioRad, Hercules, CA, USA
Sigma, St. Louis, MO, USA
MBI Fermentas Inc., Amherst, NY, USA
MBI Fermentas Inc., Amherst, NY, USA
Orbital, Hungary
Amersham, Buckinghamshire, England 
Orbital, Hungary'
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The restriction enzymes used in this study, together with their recognition and 
cleavage sites, are listed in Table 7. The enzymes were purchased from the 
designated suppliers and used according to the manufacturers’ instructions. The 
composition of the recommended buffers supplied with the restriction enzymes is also 
listed in Table 7.
2.1.5. Restriction enzymes
Table 7: Restriction Enzymes Used for iVlutation Detection
Restriction
Enzyme
Recognition
Site
Buffer
(IX)
Supplier
¡)de\
(6U/pl)
5’-C4TNAG-3’
3’-GANTTC-5’
NEBuffer .3 
lOOmM NaCi 
50 m.M Tris-HCI, pH 7.9 
10 mM MgCl.,
1 mM Dithiothreitol
Biolabs
Beverly, MA, USA
Hphl
(5U/pl)
5’-GGTGA(N)8Í -3’ 
3’-CCACT(N)7Î-5’
Buffer B
10 mM Tris-HCI, pH 7.5 
10 mM MgCb 
0.1 mg/ml BSA
MBI Fermentas Inc. 
Amherst, NY, USA
2.1.6. PCR materials
PCR kits were obtained from MBI Fermentas Inc. (Amherst, NY, USA). Kits 
contained I'hermus aqualicus DNA polymerase (5U/|.il), lOX PCR buffer (100 niM 
Tris-HCI (pH 8.8 at 25"C), 500 mM KCl, 0.8% Nonidet P40, 25 mM MgCU solution 
and 10 mM dNTP mix (one ml of 10 mM dNTP solution contains 10 pmol each of 
dATP, dCTP, dGTP, dTTP). PCR reactions were performed in 0.2 ml Thermowell
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tubes (Corning Costar Corp., Cambridge, MA, England) using the Gene Amp PCR 
system 9600 (Perkin Elmer, Foster City, CA, USA).
2.1.7. Sequencing Materials
Cycle sequencing was performed using the ABl PRISM'''* Ready Reaction 
Dye Terminator Cycle Sequencing Kit (ABl, Perkin Elmer, Foster City, C/\. USA), 
The kit contained terminator premix with A-dye terminator, C-dye terminator, G-dye 
terminator, and T-dye terminator, dlTP, dATP, dCTP and dTTP; Tris-HCl (pH 9.0); 
MgCF; thermal stable pyrophosphatase; and AmliTaq DNA polymerase, FS (8U/pl). 
Each kit also contained a pGEM‘'3Zf(+) control template (0.2 pg/pl) and -21 MI3 
forward primer (0.8 pmol/pl). Cycle sequencing reactions were performed in the 
Gene Amp PCR system 9600. Electorphoresis was performed using the 377 
Sequencer (ABl, Perkin Elmer, Foster City, CA, USA).
2.1.8. Standard Solutions and Buffers
Acrylamide: bisacrylamide stock solution (40%) (75:1)
39.5 g acrylamide 
0.53 g bisaciylamide
The volume was adjusted to 100 ml by adding ddH20.
Acrylamide: bisacrylamide stock solution (50%) (99:1)
49.5 g acrylamide 
0.5 g bisacrylamide
The volume was adjusted to 100 ml by adding ddH20.
Acrylamide: bisacrylamide stock solution (40%) (19:1)
38 g acrylamide 
2 g bisaciylamide
The volume was adjusted to 100 ml by adding ddH20
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Agarose gel loading buffer (6X)
15% ficoll
0.05% bromophenol blue 
0.05% xylene cyanol
Developer solution
1.5% NaOH 
0.1% formaldehyde
Extraction buffer
10 mM Tris HCl, pH 8.0 
10 mM EDTA, pH 8.0
0.5% SDS
F-ixative solution
10% ethanol 
0.5% acetic acid
Silver nitrate solution
0.1% silver nitrate
Sequencing loading buffer
5 parts deionized formamide 
1 part EDTA / blue dextran 
25 mM EDTA (pH 8.0)
50 mg/ml blue dextran
SSC (20X)
3 M NaCl
0.3 M trisodium citrate, pH 7.0
SSCP gel loading buffer (6X)
95% formamide 
10 mM NaOH 
0.25% bromophenol blue 
0.25% xylene cyanol
TE Buffer
10 mM Tris HCl pH 8.0 
1 mM EDTA
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Tris-boric acid-EDTA (TBE) (1 OX) (1 L)
lOSgTris HCl 
55 g boric acid 
20 ml 0,5 M EDTA 
q.s. IOOOmlddH20
2.2. Methods
2.2.1. DNA isolation from whole blood specimens
Blood can be stored at 4"C for a maximum of five days. Blood was frozen in 
700 pi aliquots in 1.5 ml eppendorf tubes at -80‘’C for at least one day before starting 
DNA isolation.
Blood was thawed and 800 pi of IX SSC was added and mixed by vortexing. 
Then, it was centrifuged in a microfuge (Heraeus instruments, Bioflige, Osterode, 
Germany) at 13,000 rpm for 1 minute. The supernatant was removed without 
disturbing the cell pellet and discarded into disinfectant. Then 1.4 ml IX SSC was 
added and the tube was vortexed briefly to resuspend the cell pellet. Again, it was 
centrifuged in a microfuge at 13,000 rpm for 1 minute and the supernatant was 
removed, avoiding the pellet. Cell pellet could be washed several times with IX SSC 
if necessary.
Next 800 pi extraction buffer (10 mM Tris HCl pH 8.0, 10 mM EDTA pH 
8.0, 0.5% SDS) and 10 pi proteinase K (20 mg/ml ddH20) were added. The tube 
was vortexed briefly to resuspend the cell pellet. The suspension was incubated at 
56"C for at least 1 hour. Incubation could be done overnight if necessary to dissolve 
the cell pellet.
The DNA was then extracted with 400 pi phenol / chloroform / isoamyl 
alcohol (25:24:1) and vortexed for 60 seconds. This step must be carried out the
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fume hood. The tube was spun in a microfuge for 5 minutes at 13,000 rpm. The 
upper aqueous layer (~700 pi) was removed and placed in a new tube. If the DNA 
supernatant was sticky or if the interface was not clear after this step, the supernatant 
is not removed. An additional extraction step was performed with 350 pi phenol / 
chloroform / isoamyl alcohol. The recovered supernatant was separated into two or 
more tubes (350 pi per tube).
The DNA was then precipitated from the suspension by adding 35 pi NaOAc 
i3M, pH 5.2) and 700 pi ice-cold absolute ethanol (EtOH) were added to each tube, 
mixed by inversion and placed at -20‘*C for 30 minutes. The tubes were spun in a 
microfuge for 15 minutes at 13,000 rpm. The alcohol was removed and the pellet was 
washed with 1.0 ml room temperature 70% EtOH. The tubes were spun in a 
microfuge for 5 minutes at 13,000 rpm. All the alcohol was removed with a 
micropipette and the tubes were left open on the bench (-'30 min) to allow the EtOH 
to evaporate. The DNA was solubilized in 200 pi TE (pH 8.0) by incubating at 56"C 
for at least 1 hour. Incubation was done overnight if necessary to solubilize the pellet. 
The DNA was then stored at -20“C.
The concentration and purity of the double stranded DNA was determined on 
the Beckman Spectrophotometer Du 640 (Beckman Instruments Inc., Fullerton, CA, 
USA) using the Beckman Instruments Du Series 600 Spectrophotometer software 
program. Absorbance readings were taken at wavelengths of 260 nm and 280 nm.
The A260 allows calculation of the concentration of nucleic acid in the sample. An 
optical density value of one corresponds to approximately 50 pg/ml of double 
stranded DNA. The A260/A280 ratio provides an estimate of the purity of the nucleic 
acid. A pure preparation of DNA will have A260/A280 ratio between 1.8 and 2.0. If
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there is contamination with protein or phenol, the A260/A280 ratio will be significantly 
less than the values given above and accurate quantitation of the amount of nucleic 
acid will not be possible.
DNA was also checked by horizontal agarose gel electrophoresis to verify that 
it was high molecular weight. A 1.0% agarose minigel with IX TBE was prepared. 
Ethidium bromide (1 pl/ml) was incorporated into the gel. DNA samples were loaded 
into the sample wells and the gel was run at 80V. After the run, the DNA was 
visualized under UV transilluminator.
2.2.2. Polymerase Chain Reaction (PCR)
PCR is a rapid procedure for in vitro enzymatic amplification of a specific 
segment of DNA. There are three distinct events in PCR: template dénaturation, 
primer annealing and DNA synthesis. Template DNA was denatured by heating the 
reaction to 95-96"C. After dénaturation the primers were allowed to hybridize to 
their complementary single-stranded target sequences. The temperature of this step 
depends on the homology of the primers for the target sequence as well as the base 
composition of the oligonucleotides. The last step was the extension of the 
oligonucleotide primer by the thermostable polymerase. Traditionally, this step was 
carried out at ITC. Usually, the larger the template, the longer the time required for 
a proper extension.
In general, 50-100 ng DNA was used as a template. A 50 pi PCR reaction
contained 5 pi lOX PCR buffer (final concentration IX PCR buffer), 1.5-3.0 mM
MgCl2, 200 pM dNTP, 10 pmol forward primer, 10 pmol reverse primer and 1 U Taq
polymerase. The volume was adjusted to 50 pi by adding ddH20. MgCb
concentration was optimized for each primer pair by setting up a series of PCR
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For radioactive PCR, the reaction volume was 25 pi and contained 2.5 pi lOX 
PCR buffer, 1.5-3.0 mM MgCb, Ю pM dNTP, 10 pmol forward primer, 10 pmol 
reverse primer, 1 U Taq polymerase and 1 pCi "P-dATP. In general, 50-100 ng 
DNA was used as a template. The volume was adjusted to 25 pi by adding ddH-20.
/amplification was performed in the GeneAmp PCR with the following 
parameters: initial dénaturation at 95“C for 3 min; 30 cycles of95‘’C foi’ 30 sec 
(dénaturation), 55"C for 30 sec (annealing), ITC  for 30 sec (extension); and a final 
extension at ITC  for 10 min. After the PCR cycles were completed, the tubes were 
held at 4 T  for at least 5 minutes or until removal.
reactions using a range of MgCb concentrations. Table 8 lists the appropriate MgCb
concentration for each exon.
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Table 8: Optimum MgCl2 concentrations for h M L H l  exon PCR
Exons Primers [MgCl.J mM
Exon 1 GA 281/282 1.5-3.0
L ____ ____________ ______________________ _
Exon 2 GA 283/284 1.5-3.0
Exon 3 GA 152/153 3.0
Exon 4 GA 285/286 3.0
Exon 5 GA 156/157 3.0
Exon 6 GA 287/288 1.5-3.0
Exon 7 GA 289/290 1.5-3.0
Exon 8 GA 291/292 1.5-3.0
Exon 9 GA 164/165
______________________
1.5-3.0
Exon 10 GA 333/334 3.0
Exon 11 GA 337/338 3.0
Exon 12 GA 339/340 3.0
Exon 13 GA 343/344 3.0
Exon 14 GA 293/294 1.5-3.0
Exon 15 GA 172/173 3.0
Exon 16 GA 345/346 3.0
Exon 17 GA 176/177 1.5-3.0
Exon 18 GA 178/179 1.5-3.0
Exon 19 GA 180/181 1.5-3.0
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2.2.3. Restriction Enzyme Digestion
Restriction enzyme digestions with Dde\ and Hph\ were performed in 20 p,! 
reaction volumes using the reaction buffer recommended by the manufacturer. One 
unit of enzyme was sufficient to digest approximately 30-50 ng PCR product. The 
PCR template was quantitated by agarose gel electrophoresis using a DNA size 
marker of known concentration. The incubation temperature was 37“C for both 
enzymes. After digestion, heat inactivation was performed at 65“C.
After incubation the cut and uncut PCR fragments were analyzed by agarose 
gel electrophoresis. DNA size markers were used to calculate the sizes of the bands 
by drawing a standard curve for the particular marker used. Electrophoresis was 
performed using 4% NuSieve 3:1 agarose at 5 V/cm in IX TBE for 2.5 hours. After 
the electrophoresis, the gel was stained in EtBr (1 pg/ml) for 20 minutes and then 
destained by two 15-minute washes with distilled water.
2.2.4. HeterodupJex Analysis (HA)
HA was performed using the EC 160 (E-C Apparatus Corp., Holbrook, NY, 
USA) electrophoresis apparatus and the Power-PAC 3000 power supply (BioRad, 
Hercules, CA, USA) with the following acrylamide and MDE gel formulations:
6% acrylamide (100 ml)
15 ml acrylamide 19:1 
75 ml ddH20 
10 ml lOXTBE 
400 pi 10% APS 
40 pi TEMED
MDE gel (75 ml)
28 ml MDE gel (2X) 
36.4 ml ddHaO
4.5 ml 1 OX TBE
5.6 ml Glycerol 
400 pi 10% APS
40 pi TEMED
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All gel components except for APS and TEMED were mixed and just before 
pouring 10% APS and TEMED were added. The gel was allowed to polymerize for 
at least 2 hours. The standard running buffer was 0.6X TBE for MDE gel and 1X 
TBE for acrylamide gel.
The HA reaction was performed by heating 15 pi PCR product at 95"C for 5 
minutes in the Perkin Elmer GeneAmp PCR 9600 system to denature the double 
stranded DNA. The denatured DNA samples were allowed to anneal at room 
temperature for 30 minutes. Then 3pl 6X loading buffer (15% ficoll, 0.05% xylene 
cyanol, 0.05% bromophenol blue) was added to each tube and 4pl was loaded onto 
the gel. Electrophoresis was performed at 5W constant power at room temperature 
(25"C),
After electrophoresis, the DNA bands were visualized by silver staining. The 
gel was washed two times with ddH^O for one minute, then treated two times with 
fixative solution for 3 minutes and again washed with ddH20. In the next step the gel 
was stained for 10 minutes with 0.1% silver nitrate solution. The silver nitrate 
solution was discarded and the gel was rapidly washed twice with ddH20. Finally, the 
gel was treated with ice-cold developer solution for about 30 minutes. Once the 
DNA bands were observed, the gel was placed into 7.5% acetic acid solution for 10 
minutes to stop the reaction.
2.2.5. Single-Strand Conformation Polymorphism (SSCP)
Three different SSCP gel formulations were evaluated: 10% 75:1 acrylamide: 
bisacrylamide, 6% 75:1 acrylamide: bisacrylamide and 10% 99:1 acrylamide: 
bisacrylamide. All gels contained 10% glycerol, a neutral compound that alters the
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strand separation and increases the resolution. The acrylamide gel formulations are 
given below:
10% acrylamide (100 ml)
25 ml acrylamide 75:1 or 99; 1 
59 ml ddH20 
6 ml lOXTBE 
10 ml glycerol 
400 pi 10% APS 
40 pi TEMED
6% acrylamide (100 ml)
15 ml aci^lamide 75:1 
69 ml ddH20 
6 ml lOXTBE 
10 ml glycerol 
400 pi 10% APS 
40 pi TEMED
All the gel components except APS and TEMED were combined and filtered 
using a Nalgene apparatus with 0.2 pm cellulose acetate filters (Corning Costar 
Corp., Cambridge, MA, England) and a Hetomaster jet water pump (Heto-Holten 
A/S, Allerod, Denmark). Vacuum was applied for 5 minutes in order to degas the 
acrylamide solution. Immediately before pouring the gel 10% APS and TEMED were 
added. The gel was allowed to polymerize for at least 2 hours. The standard running 
buffer was 0.6X TBE. For gels run on the Genomyx system, the upper buffer was 
0.6X TBE and the lower buffer was I X TBE.
Three gel electrophoresis apparatuses were used: EC 160 and EC 175 (E-C 
Apparatus Corp., Holbrook, NY, USA) and Genomyx (Genomyx, Foster City, CA, 
USA). A Power-PAC 3000 power supply (BioRad, Hercules, CA, USA) was used 
with the EC 160 and EC 175. A comparison of the gel sizes and electrophoresis 
conditions used with each is given in Table 9.
The SSCP reaction was performed by mixing 2 pi PCR product with 18 pi 
SSCP loading buffer (95% formamide, 10 mM NaOH, 0.25% bromophenol blue, 
0.25% xylene cyanol), heating at 95"C for 2 minutes and putting the tubes on ice for 5 
minutes. The samples were then immediately loaded onto the gel. Electrophoresis
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was performed at constant power (5, 20 or 45W) depending on the gel apparatus, at 
room temperature (25“C) or at 4°C, After electrophoresis, the gel was removed from 
glass plates using Whatman 3MM paper and dried on the SGD 2000 slab gel dryer 
(Savant, Holbrook, NY, USA) at 80“C for 2 hours. Radioactive bands were detected 
by autoradiography or phosphoimaging.
Table 9: Comparison of Gel Apparatuses used for SSCP Analysis
EC 160 EC 175 Genoniyx
Gel Size 
Well Capacity
33 cm X 42 cm 15 cm X 28 cm 35 cm X 65 cm
4-6 III
”45 w '
20 pi
■5 w "
4 pi
.......20W.......
T3Ó'Ó-200Ó'V
Power
Voltage 1500-2200 V 
” '¿O^o’mA'”
........r c .......
400-1000 V 
”” 5-T3mA” ’ 
’4°Cand25°c'
Current
Temperature 25"C
For autoradiography, the dried gel was placed into a cassette with X-ray film 
(Kodak, Rochester, NY, USA) and an intensifying screen. The cassette was placed at 
-80T for exposure. After the exposure, the film was developed using a 
Hyperprocessor developer (Amersham, Buckinghamshire, England).
Phosphoimaging was performed using the Molecular Imager“ System, GS-525 
(BioRad, Hercules, CA, USA). The dried gel was placed into the cassette and a foil 
protector placed on top. A clean, erased image screen was then placed over the gel. 
After exposure, the screen was placed in the scanner and the data captured using 
Multi-Analyst software. This method allows one to adjust the contrast and brightness 
for the best band resolution.
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2.2.6. DNA Sequence Analysis
DNA sequence analysis of hMLHJ exon 15 was performed for samples 98-05 
and 97-630 using primers GA 172 (forward primer) for the sense strand sequence and 
GA 173 (reverse primer) for the antisense strand sequence. The primers for hM lJiI 
exon 7 GA 289 (forward primer) for the sense strand sequence and GA 290 (reverse 
primer) for the antisense strand sequence. The PCR template was quantitated by 
agarose gel electrophoresis using a DNA size marker of known concentration. Cycle 
sequencing reactions were set up in 0.2 Thermowell'''' tubes (Corning Costar Corp., 
Cambridge, MA, England) as follows:
Cycle sequencing reaction
3-6 pi 
1 pi 
4 pi
___
20 pi
Template (10-30 ng/pl PCR product) 
Primer (3.2 pmol)
Terminator ready reaction mix 
ddH20
Cycle sequencing reactions were performed in either the Perkin Elmer 
GeneAmp PCR 9600 system or 2400 thermal cyclers according to the following 
protocols;
Cycle Sequencing Protocol
Sense Strand (GA 172) Antisense Strand (GA 173)
98“C X 20 sec 98T x 20 sec
98‘C  X 10 sec
50"C X 5 sec 30 cycles 
60‘C x 4 m in  _
4"C hold
96T  X 10 sec 
50"C X 5 sec 
60"C X 4 min 
4"C hold
30 cycles
Sequencing products (20 pi) were precipitated by adding 68 pi cold absolute
EtOH and 7 pi 7.5 M ammonium acetate and placing on ice for 15 min. The DNA
51
was pelleted by centrifijged at 13,000 rpm for 15 min, washed with 250 pi cold 70% 
EtOH and air dried. The DNA pellet was resuspended in 6 pi sequencing loading 
buffer and 2 pi were loaded on the gel.
Polyacrylamide gel electrophoresis was performed using standard conditions 
on a 377 Prism sequencer (ABl). The standard sequencing gel contained 4% 
acrylamide/bisacrylamide (19:1), 7 M urea, and 1X TBE:
4% sequencing gel solution (50 ml)
19 g urea dissolved in 25 ml ddl-BO
5 ml 40% acrylamide / bisacrylamide (19:1)
5 ml lOXTBE
q.s. ddH20 (to 50 ml)
250 pi 10% APS
34 pi TEMED
Electrophoresis conditions were 29 W, 18 mA, 1.65 kV and the temperature 
was 50"C. Electrophoresis was carried out for approximately 5-7 hours depending on 
the maximum fragment length.
The data was collected by ABI data collection software during 
electrophoresis. After the run finished, the collected data was automatically analyzed 
by ABl sequencing analysis software. The analyzed files were then imported into the 
Factura program to identify the unambiguous sequences. These analyzed sequences 
were then imported into the Sequencing Navigator for alignment with the reference 
DNA sequence.
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3. Results
3.1. DNA Isolation
Genomic DNA was isolated from patient blood using a phenol chloroform 
extraction method. All extracted DNAs were evaluated quantitatively and 
qualitatively by UV spectrophotometry and agarose gel electrophoresis. An example 
is shown in Figure 11. Although the sample in lane 1 is high molecular weight DNA, 
the A260/A280 ratio was 1.3, which indicated poor quality. The extraction was 
repeated but the same results were obtained, probably because the blood sample had 
partially coagulated. The samples in lanes 2-4 all have high molecular weight DNA 
of good quality. Their A260/A280 ratios were —1.7. The concentrations of these DNA 
samples are 100, 50, 182 and 86 p.g/ml, respectively.
Figure 11: Analysis of extracted genomic DNA.
Samples were electrophoresed through a 1% agarose gel at 8V/cm for 1 hour. Lane 
1: sample 96-16, Lane 2: sample D, Lane 3: sample MRl, Lane 4; sample MR2.
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3.2. Polymerase Chain Reaction
All PCR products were evaluated by agarose gel electrophoresis. The samples 
shown in Figure 12 were amplified by hMLHl exon 10 primers, GA 333 and GA 334. 
The expected size of the PCR product was 227 bp and this was confirmed by 
comparison of the observed DNA band with the size marker. The negative control 
sample has no DNA band indicating that the PCR mixture contained no contaminating 
DNA.
Figure 12; Analysis of PCR products.
Samples were electrophoresed through a 2% agarose gel at 8V/cm for 35 min. Lane 
1: 0X174 DNA/f/wfl marker, Lane 2: sample 96-16, Lane 3: sample 96-17, Lane 4: 
sample 96-19, Lane 5: negative control.
3.3. Detection of G884C hMLHl mutation by Ddel digestion
A G884C point mutation was previously identified in the proband of the 
HNPCC I kindred (Wang et al., 1997). This point mutation is a missense mutation 
that results in a Ser->Thr amino acid substitution at codon 295. The mutation occurs 
within the recognition site of the restriction enzyme Ddel and results in a loss of the 
restriction site. Thus, digestion of the hMLHl exon 10 PCR product with Ddel might
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provide a simple, cost-effective assay for identifying other members of the HNPCC 1 
kindred who inherited the same mutation.
Dde\ has two recognition sites in the wild type hMLHl exon 10 DNA 
sequence. The PCR amplified fragment is 227 bp. After Dde\ digestion the expected 
fragment sizes are 132 bp, 69 bp and 26 bp (schematically depicted in Figure 13). 
When there is a G884C mutation, one Dde\ site is lost. In a heterozygous individual 
the expected fragment sizes are 201 bp, 132 bp, 69 bp and 26 bp (Figure 13).
Amplified hMLHl exon 10 PCR products were incubated with Ddel in the 
recommended buffer at 37“C for 2 hours. As a control, amplified hMLHl exon 10 
PCR products were also incubated in the same Ddel buffer except without the 
enzyme. After digestion the DNA samples were analyzed by agarose gel 
electrophoresis. A standard curve for the 0X174 DNA //wfl fragments was drawn 
showing the distance migrated (mm) vs the size (logarithm bp). The sizes of the 
Di/t;I-digested DNA fragments were then calculated using this curve (data not 
shown).
The Ddel digestion results for individual 96-18 are shown in Figure 14. From 
the digestion profile it is obvious that individual 96-18 is heterozygous. Both the 96- 
18 sample and the control sample show a single band when Ddel is not added to the 
reaction buffer. However, after Ddel digestion there are three visible bands in the 96- 
18 sample but only two visible bands in the control sample (the 26 bp fragment is too 
small to detect with this agarose concentration). The sizes of the Difel-digested bands 
in the 96-18 sample were calculated to be 200, 132 and 65 bp. The sizes of the Ddel- 
digested bands in the control sample were calculated to be 132 bp and 65 bp. These 
values are very close to the expected values. Thus, one can conclude that individual 
96-18 is heterozygous for the G884C mutation.
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Codon 295 
ACT -> ACT 
Ser -> Thr 
Dde\ Digestion
h M L H l, Exon 10, 227 bp
Wild-type
26bp I  132bp I  69bp 
----- *■ 227bp <----
Mutant
26bp I ________ 201 bp
----- > 227bp
5’—CTCAG 
3’ -g a g y :
CTCAG -3’ 
G A G ^ -5’
5’—CTCAG 
3’-~GAGY
CTCAC -3’ 
GAGTG—5’
Wild-type Heterozygous Mutant
132 bp
69 bp
26 bp
201 bp
26 bp
Figure 13: Expected Dde\ fragment sizes for wild-type, heterozygous and 
homozygous mutant individuals.
Red arrows indicate the recognition / cleavage sites of Dde\.
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227bp
Figure 14: Ddel digestion profile.
DNA fragments were electrophoresed in 4% NuSieve 3:1 agarose at 5V/cm for 2.5 
hours. Lane 1: 0X174 D NKH inil marker, Lane 2: undigested control, Lane 3: 
Drfel-digested control. Lane 4: undigested 96-18, Lane 5; Dcfel-digested 96-18.
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DNA samples of five family members from the HNPCC 1 kindred (Figure 6) 
were analyzed using this method. Initially, conclusive results were obtained for only 
three of the five family members; two DNA samples were only partially digested with 
Ddel. Increasing the increased amount of enzyme and/or the time of incubation did 
not help. However, complete digestion was obtained when the PCR products were 
purified with QIAquick PCR purification kit (QIAGEN, Chatsworth, CA, USA) prior 
to Ddel digestion. The results are presented in Table 10. Two individuals (96-17 and 
96-19) have two wild-type alleles. Three family members (96-15, 96-16 and 96-18) 
are heterozygous for the mutant allele. These results were confirmed DNA sequence 
analysis (performed by B. Cevher).
Table 10: Detection of G884C hM LHl mutation by Ddel digestion
Family
Member
Genotype 
Ddel digestion
Phenotype Age
96-15 + / - colon cancer 39‘"
96-16 + / - no disease 18
96-17 + / + no disease 75
96-18 + / - no disease 9
96-19 + / + no disease 17
“Age at diagnosis.
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An A1652C point mutation was previously identified in the proband of the 
HNPCC 2 kindred (Wang et al., 1997). This point mutation is a missense mutation 
that results in a Asn^Thr amino acid substitution at codon 551. This mutation 
creates a recognition site for the restriction enzyme Hphl. Because Hphl cleaves the 
mutant sequence but does not cleave the wild-type sequence, digestion of the hMLHl 
exon 14 PCR product with Hphl might provide a simple, cost-effective assay for 
identifying other members of the HNPCC 2 kindred who inherited the same mutation.
Hphl has no recognition site in the wild type hMLHl exon 14 DNA sequence. 
The PCR amplified fragment is 254 bp. The A1652C mutation introduces an Hphl 
site. In a heterozygous individual the expected fragment sizes are 254 bp, 183 bp and 
71 bp (schematically depicted in Figure 15).
Amplified hMLHl exon 14 PCR products were incubated with Hphl in the 
recommended buffer at 37“C for 2 hours. As a control, amplified hMLHl exon 14 
PCR products were also incubated in the same Hphl buffer, except without the 
enzyme. After digestion the DNA samples were analyzed by agarose gel 
electrophoresis. A standard curve for the 0X174 DNA Hinil fragments was drawn 
showing the distance migrated (mm) vs the size (logarithm bp). The sizes of the 
///;/il-digested DNA fragments were then calculated using this curve (data not 
shown).
3.4. Detection of A1652C hM L H l mutation by H ph\ digestion
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Codon 551 
AAC ^  ACC 
Asn Thr 
Hphl Digestion
h M L H l, Exon 14, 254 bp
Wild-type
-► 254bp
Mutant
183bp I  71bp 
254bp -----
5’—(N7)TCAAC—3’ 
3’—(N8)AGTTG—5’
i
5’—(N7)TCACC—3’ 
3’~|(N8)AGTGG -5’
Wild-type Heterozygous Mutant
254 bp
183 bp 
71 bp
Figure 15: Expected Hphl fragment sizes for wild-type, heterozygous and 
homozygous mutant individuals.
Red arrows indicate the recognition / cleavage site of Hphl.
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The Hphl digestion results for individual 97-160 are shown in Figure 16.
From the digestion profile it is obvious that individual 97-160 is heterozygous. Both 
the 97-160 sample and the control sample show a single band when Hphl is not added 
to the reaction buffer. Flowever, after Hphl digestion there are three bands visible in 
the 97-160 sample but only one band visible in the control sample. The sizes of the 
Hphl -digested bands in the 97-160 sample were calculated to be 251, 182 and 70 bp. 
The size of the Hphl -digested band in the control sample was calculated to be 251 
bp. These values are very close to the expected values. Thus, one can conclude that 
individual 97-160 is heterozygous for the A1652C mutation.
1 2 3 4 5
«BiMtt «SI 4^]
> 254bp
► 183bp
71bp
Figurel6: Hphl digestion profile.
DNA fragments were electrophoresed in 4% NuSieve 3:1 agarose at 5V/cm for 2.5 
hours. Lane 1: 0X174 DNA///«f I marker. Lane 2: undigested control. Lane 3: 
/^pM-digested control. Lane 4; undigested 97-160, Lane 5: .i^/^M-digested 97-160.
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DNA samples of 29 family members from the HNPCC 2 kindred (Figure 7) 
were analyzed using this method. The results are presented in Table 11. Conclusive 
results were obtained for all family members tested. Seventeen individuals have an 
Hphl digestion profile consistent with wild-type. Twelve individuals have an Hphl 
digestion profile consistent with heterozygosity. DNA sequence analysis confirmed 
the results for twelve of thirteen samples. Sample 97-184 was reported to be wild- 
type (Wang et al., 1997). However, repeat DNA sequence analysis of sample 97-184 
(performed by B. Cevher) verified that our DNA sample was heterozygous for the 
mutation.
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Table 11: Detection of A1652C hM LH I mutation by H phl digestion
Family
Member
1 Genotype 
Hphl digestion
DNA Sequence 
Confirmation
Phenotype Age
97-160 J + / - yes colon cancer 47“
97-161
1
+ / - yes colon cancer 33“
97-162 \ + / + yes no disease 39
97-163 ; + / - yes no disease 34
97-164
1
+ / - yes no disease 31
97-165 + / + yes ovarian cyst 45
97-166
1
+ / - not done no disease 40
97-167 1 + / + not done no disease 40
97-168 + / - not done no disease 36
97-169 ; + / + not done no disease 18
97-170 i + / + not done no disease 14
97-171 j + / + yes no disease 51
97-172 + / + not done no disease 22
91-173 + / + not done no disease 18
97-174 ; + / + yes no disease 45
97-175 ; + / + not done no disease 41
97-176 + / + not done no disease 26
97-177 1 + / - not done no disease 32
97-178 ; + / + not done no disease 28
97-179 + / + not done no disease 48
97-180 + / - not done no disease 14
97-181 1 + / + not done no disease 18
97-182 1 + / - yes no disease 32
97-183 + / - yes no disease 45
97-184 + / - yes no disease 41
97-185
1
+ / + not done no disease 43
97-186 I + / + not done no disease 43
97-187 J + / - yes no disease 34
97-188
1
+ / + yes no disease 33
“Age at diagnosis.
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3.5. Heteroduplex Analysis
Four cell lines with known mutations were analyzed by heteroduplex analysis. 
The samples were run on 6% non-denaturing gel electrophoresis and the bands were 
observed by silver staining. However, we were not able to detect any migration 
difference between the mutant PCR products and the control PCR products. This is 
probably due to the insensitivity of the method with silver staining.
3.6. Single Strand Conformation Polymorphism
3.6.1. Detection of known mutations
DNA samples with known mutations were used as controls to define SSCP 
conditions that would detect both point mutations and insertion/deletion mutations. 
Use of these samples demonstrated the accuracy and the efficiency of a specific 
method in mutation screening. The nine DNA samples listed in Table 12 represent 
three transversion mutations, two transition mutations and one small deletion.
Table 12: Defined hM LH l mutations
Exon Mutation (Type) Codon Change Sample
3 G293C (transversion) Gly98Ala HNPCC 4
6 A544G (transition) Argl82Gly CL 11872
8 A655G (transition) Ile219Val* HNPCC 4
8 C676T (transition) Arg226stop HNPCC 3
10 G884C (transversion) Ser295Thr HNPCC 1
14 A1652C (transversion) Asn551Thr HNPCC 2
15 G1672T (transversion) Glu558stop CL 13481
16 1846-1848 deletion del Lys 616 CL 12826
17 G1989T (transversion) Glu663Asp CL 13158
* Polyinorphism
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The nine DNA samples with known mutations were analyzed using seven 
SSCP protocols. The ability of the different protocols to detect the known mutations 
is summarized in Table 13. The three base pair deletion was the easiest mutation to 
detect; it was detected using five protocols (1, 2, 5, 6 and 7). In terms of the variety 
of mutations detected, protocol 2 was the most successful, detecting five of the nine 
mutations. Both protocol 1 and protocol 7 were able to detect multiple mutations 
(three and two, respectively). Protocols 3, 4, 5 and 6 detected one mutation each. 
The two A-»G transition mutations were not detected using any of these protocols.
Table 13: Detection of known mutations by SSCP
Mutation Protocol Apparatus Acryl % Acryl: Bis Power Temp Time
G293C 1 EC 160 10% 99:1 45 W 4"C 14hrs
A544G not detected
A655G not detected
C676T 2 EC 175 10% 99:1 5W 4”C 30 hrs
G884C 7 Genomyx 6% 75:1 20W 25“C 10 hrs
A1652C 2 EC 175 10% 99:1 5W 4“C 22 hrs
3 EC 175 10% 75:1 5W 4"C 30 hrs
G1672T 1 EC 160 10% 99:1 45W 4"C 14 hrs
2 EC 175 10% 99:1 5W 4"C 30 hrs
1846-48 1 EC 160 10% 99:1 45W 4“C 14 hrs
AAAG 2 EC 175 10% 99:1 5 W 4”C 30 hrs
5 Genomyx 10% 99:1 20W 25“C 15 hrs
6 Genomyx 10% 75:1 20W 25"C 13 hrs
7 Genomyx 6% 99:1 20W 25T 10 hrs
G1989T 2 EC 175 10% 99:1 5W 4“C 14 hrs
4 EC 175 10% 75:1 5W 25"C 30 hrs
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Sample 97-630 is from an HNPCC individual with a G293C transversion in 
exon 3 that results in a Gly-^Ala substitution at codon 98. When analyzed by SSCP 
protocol 1, this PCR product showed four DNA bands whereas PCR products from 
an unrelated HNPCC individual (98-05) and a normal control showed only two DNA 
bands (Figure 17). This mutation was not detected using any other SSCP protocol.
1 2 3
■< ■ ■
Figure 17: Detection of G293C transversion [codon 98].
Lane 1: sample 97-630, Lane 2: sample 98-05, Lane 3: control sample. SSCP gel was 10% 
99:1 acrylamide:bisacrylamide. Electrophoresis was performed on the EC 160 at 45W 
constant power at 4“C for 14 hours. Autoradiography was at -80“C for 5 days. Arrows 
indicate shifted bands in mutant sample.
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Sample 97-195 is from an HNPCC individual with a C676T transition 
mutation in exon 8 that results in an Arg->stop substitution and protein truncation at 
codon 226, When analyzed by SSCP protocol 2, this PCR product showed three 
bands whereas the control PCR product showed only two bands (Figure 18). This 
mutation was not detected using other SSCP protocols.
1
:
rk'*'· *'■
Figure 18: Detection of C676T transition [codon 226].
Lane 1: sample 97-195, Lane 2; control sample. SSCP gel was 10% 99:1 acrylamide: 
bisacrylamide. Electrophoresis was performed on the EC 175 at 5W constant power at 4"C 
for 30 hours. Autoradiography was at -80"C for 5 days. Arrow indicates shifted band in 
mutant sample.
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Sample 96-15 is from an HNPCC individual with a G884C transversion 
mutation in exon 10 that results in a Ser-^Thr substitution at codon 295. When 
analyzed by SSCP protocol 7, this PCR product showed an altered mobility compared 
to the control PCR product. Both samples have three bands but the patterns of these 
bands is different (Figure 19). The uppermost band of sample 96-15 is higher than the 
uppermost band of the control sample. This mutation was not detected using any 
other SSCP protocol.
1 2
. "t'
Figure 19: Detection of G884C transversion [codon 295].
Lane 1: sample 96-15, Lane 2: control sample. SSCP gel was 6% 75:1 acrylamide: 
bisacrylamide. Electrophoresis was performed on Genomyx at 20W constant power at 25“C 
for 10.5 hours. Autoradiography was at -80“C for 8 days. Arrows indicate bands with 
differential mobility.
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Samples 97-160 and 97-161 are from two HNPCC individuals from the same 
family. The inherited mutation in this family is an A1652C transversion in exon 14 
that results in an Asn->Thr substitution at codon 551. When analyzed by SSCP 
protocol 2, the mutant PCR products displayed two bands, while the control sample 
showed only one (Figure 20). This mutation was also detected using SSCP protocol 
3 (data not shown).
» .vtr, V-'· 
-4·; ·
Figure 20: Detection of A1652C transversion [codon 551].
Lane 1: sample 97-160, Lane 2: sample 97-161, Lane 3: control sample. SSCP gel was 10% 
75:1 acrylamide:bisacrylamide. Electrophoresis was performed on the EC 175 at 5W 
constant power at 4"C for 22 hours. Autoradiography was at -80®C for 3.5 days. Arrow 
indicates extra band in mutant samples.
69
The cell line 13481 has a G1672T transversion mutation in exon 15 that 
results in a Glu->^stop substitution at codon 558. When analyzed by SSCP protocol 
2, the mutant PCR product shows four bands, while the control PCR product shows
only two bands (Figure 21). This mutation was also detected using protocol 1 (data 
not shown).
Figure 21: Detection of G1672T transversion [codon 558].
Lane 1: cell line 13481, Lane 2: control sample. SSCP gel was 10% 99:1 acrylamide: 
bisacrylamide. Electrophoresis was performed on the EC 175 at 5W constant power at 4"C 
for 30 hours. Autoradiography was at -80“C for 5 days. Arrows indicate extra bands seen in 
mutant sample.
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The cell line 12826 has 3 bp deletion in exon 16 that results in deletion of Lys 
codon 616. This mutation was detected by five SSCP protocols: numbers 1, 2, 5, 6 
and 7. The SSCP results using protocol 7 are shown in Figure 22. The mutant PCR 
product migrates as two distinct single-stranded molecules, while the control PCR 
product migrates as a single broader band.
Figure 22: Detection of AAG deletion [codon 618].
Lane 1: cell line 12826, Lane 2; control sample. SSCP gel was 6% 75:1 acrylamide: 
bisacrylamide. Electrophoresis was performed on the Genomyx apparatus at 20W constant 
power at 25"C for 10.5 hours. Autoradiography was at -80"C for 8 days. Arrow indicates 
extra band present in mutant sample.
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The cell line 13158 has a G1989T transversion mutation in exon 17 that 
results in a Glu^Asp substitution at codon 663. When analyzed using SSCP 
protocol 4, the mutant PCR product shows three bands, while the control PCR 
product shows only two (Figure 23). This mutation was also detected using SSCP 
protocol 2.
1
- ' ' '
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Figure 23: Detection of G1989T transversion [codon 663].
Lane 1: cell line 13158, Lane 2: control sample. SSCP gel was 10% 75;1 acrylamide: 
bisacrylamide. Electrophoresis was performed on the EC 175 at 5W constant power at room 
temperature for 14 hours. Autoradiography was at -80"C for 3 days. Arrow indicates extra 
band seen in mutant sample.
The A->G transition mutations in exons 6 and 8 were analyzed using all seven 
SSCP protocols. Unfortunately, no mobility difference was detected between these 
samples with known mutations and control samples.
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3.6.2. Detection of unknown mutations
hMLHI mutation screening for the HNPCC 5 proband was carried out using 
the SSCP protocols previously determined to have good detection capabilities. All 19 
exons in both proband and control DNA samples were amplified by radioactive PCR, 
The PCR products were then analyzed using three SSCP protocols (Table 14), The 
results are presented in Table 14.
Table 14: SSCP Mutation Screening for HNPCC 5 proband
Exons Apparatus Acryl % Power Temp Time Mobility
Difference
1-19 EC 160 10% 99:1 45W 4°C 14 hr exon 7 
exon 15
15 EC 175 10% 99:1 5W 4 T 30 hr exon 15
1-19 Genomyx 10% 99:1 20W 25‘’C 15 hr exon 15
Comparison of the SSCP results for the HNPCC 5 proband with those for 
normal controls hMLHI revealed a differential strand mobility for exon 15 using all 
three SSCP protocols. As seen in Figure 24, three bands were observed for cell line 
13481 (G1672T transversion, exon 15), sample 97-630 (G293C transversion, exon 
3), and a normal control sample, whereas only two bands were observed for sample 
98-05. Because the migration of sample 98-05 is markedly different from the other 
samples, this might reflect a DNA sequence difference.
SSCP analysis of hMI.Hl exon 7 also showed differential migration for the 
proband and the normal control (Figure 25). The control sample has three bands, 
whereas the 98-05 sample has only two bands. This difference might be due to 
differences in the DNA sequence.
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Figure 24: Mobility shift in hM LH l exon 15 of the HNPCC 5 proband.
Lane 1: cell line 13481, Lane 2: control sample. Lane 3: proband sample 98-05, Lane 4; 
sample 97-630. SSCPgelwas 10% 99:1 acrylamide:bisacrylamide. Electrophoresis was 
performed on the Genomyx apparatus at 20W constant power at 25“C for 15 hours. 
Autoradiography was at -80”C for 5 days.
Figure 25: Mobility shift in hM LH l exon 7 of the HNPCC 5 proband.
Lane 1: sample 98-05, Lane 2: control sample. SSCP gel was 10% 99:1 acrylamide: 
bisacrylamide. Electrophoresis was performed on the EC 160 apparatus at 45W constant 
power at 4“C for 14 hours. Autoradiography was at -80"C for 6 days.
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3.7. DNA Sequence Analysis
3.7.1. hM LH l exon 15
Cycle sequencing reactions using template 98-05 DNA, 97-630 DNA and 
control DNA were carried out using the hMLHl exon 15 primers, GA 172 and GA 
173 and the ABI PRISM kit. The DNA products were then analyzed by 
electrophoresis on the 377 DNA Sequencer with ABI Sequence Analysis software. 
Heterozygous bases were identified using the Factura software program. Finally, the 
DNA sequence was aligned with the reference sequence using the Sequence 
Navigator software program (Appendix C). The sample 98-05 exon sequence 
(nucleotides 89 to 175) was identical to the reference sequence. The only difference 
occurred at nucleotide 88 in the intron. At this position, the 98-05 DNA sequence 
was determined to be an A (adenine) residue, while the control DNA sequence was 
determined to be heterozygous “R” with one allele having an A (adenine) residue at 
this position and the other allele having a G (guanine) residue at this position (Figure 
26). The 97-630 DNA sequence was also heterozygous at this position. Thus, the 
SSCP migration difference is most likely due to this intronic polymorphism.
3.7.2. hM LH l exon 7
The nucleotide sequence of hMLHl exon 7 was determined for samples 98-05 
and a control sample as described above, except that the exon 7-specific primers GA 
289 and GA 290 were used. Until now, only the sense strand sequence has been 
obtained using the forward primer. Alignment of the 98-05 sequence with the 
reference sequence (Appendix D) reveals no discrepancy in the region for which clear 
data was available (nucleotides 51 to 93).
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a : T A A A G T ' ' C A C T  T C A T T  T
V '· -
c·. T A A A G T C R C T  T C A T T  T
d: T A A A G T C R C T T C A T T T
y^ c::iX>CVkv^ -^ -"
Figure 26. Intronic polymorphism in hM LHl intron 15.
a. Sample 98-05: DNA sequence obtained with forward primer, b. sample 98-05: DNA 
sequence obtained with reverse primer; c. control: DNA sequence obtained with forward 
primer; d. control: DNA sequence obtained with reverse primer. Arrow indicates intronic 
polymorphism in control DNA sample.
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4. Discussion
HNf^CX’ is a relatively common hereditary disease that affects approximately 1 
in 200 to 1,000 individuals and accounts for 3% of all colorectal cancers (Boland,
1998). Defects in five DNA mismatch repair genes, hMLHl, liMSH2, hPMSJ, 
HFMS2, and hMSH6, have been linked to HNPCC, with the majority of the mutations 
occurring in hMLHl and hMSH2. Individuals with a germline mutation in one of the 
DNA mismatch repair genes have a much greater risk of developing colorectal cancer.
Detection of mutations in these tumor susceptibility genes is extremely 
important for HNPCC individuals. If a germline mutation is identified, then 
preventive screening for colorectal tumors and other tumors typically associated with 
HNPCC can be done. If a tumor is discovered early, then surgical intervention might 
be curative. In addition, identification of unaffected individuals is also important. 
Individuals who do not have the mutation need not undergo unnecessary, invasive 
tests that otherwise would have been advised based on the family history.
This study proposed to identify possible germline mutations in the DNA 
mismatch repair gene, hM lH l, in HNPCC kindreds. Restriction enzyme analysis was 
used to analyze known mutations that affected a recognition/cleavage site. Single­
strand conformation polymorphism (SSCP) analysis was used to scan the entire 
hMLHI coding region for unknown mutations. Finally, DNA sequence analysis was 
performed to confirm these results.
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Although the Amsterdam criteria are very useful in defining HNPCC kindreds, 
they are often too restrictive. Germline mutations in mismatch repair genes have been 
demonstrated in families that did not meet the Amsterdam criteria (Beck et al.,
1997b). The HNPCC 5 family does not fulfill the Amsterdam criteria because there 
are only two first-degree family members affected with colorectal cancer and because 
neither individual was diagnosed before the age of 50. This particular family was 
included as a potential HNPCC family because many other family members are 
affected with other cancers, such as stomach, larynx, esophagus, ovarian and possibly 
liver cancer. If the criteria are modified to include slightly older individuals with 
tumors typically found in HNPCC families, then the HNPCC 5 family can be included. 
Too rigid interpretation of the Amsterdam criteria may eliminate true HNPCC 
families, while a more relaxed interpretation may increase the identification of 
potential HNPCC families.
The specificity and sensitivity of the SSCP mutation detection method is not 
100%. For example, SSCP is not able to detect whole exon deletions, which occur in 
some HNPCC families (Cotton, 1997). Moreover, some mutations, particularly point 
mutations and frameshift mutations are not detected by SSCP (Beck et al., 1997a) and 
this is a great concern. Although modification of SSCP conditions may increase the 
detection rate, this necessity of performing multiple screens increases both the cost 
and the time required for diagnosis.
In the HNPCC 1 family, three heterozygous individuals and two normal 
individuals were determined by l)de\ analysis. These results were confirmed by DNA 
sequence analysis. Two of the heterozygous individuals are very young (9 and 18 
years old). If and when the parents (and possible the teenager) are informed, it is
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important that the genetic counselor be able to give appropriate psychological 
support.
The HNPCC 1 defect is a missense mutation G884C that causes a Ser->Thr 
substitution. The effect of this substitution on the structure and lianction of the 
MLHl protein is not known. However, several observations support the conclusion 
that this is a pathogenic mutation and not simply a polymorphism. First, no G884C 
transversion was found in 50 unrelated individuals from Turkish population (Wang et 
al., 1997). Second, the G884C mutation was identified in tumors of affected family 
members with the loss of wild-type allele (Wang et al., 1997). The serine to threonine 
substitution is a conservative substitution. Both amino acids are hydrophilic with 
uncharged hydroxyl side chains. These amino acids often participate in hydrogen 
bond formation to other polar molecules. Threonine has longer side chain. Since this 
mutation is present near a conserved region (Figure 4), it might have an effect on the 
conformation and, therefore, function of the protein. Serine residues can be potential 
0-linked glycosylation sites or phosphorylation sites. However, it is not known 
whether the serine 295 residue has this function.
In the HNPCC 2 family, Hph\ restriction enzyme analysis determined that 12
out of 29 individuals were heterozygous for the A1652C mutation. This mutation
cosegregates with the disease as seen in the family pedigree (Figure 7). There is only
one tested heterozygous individual who is older that 50 and does not have colorectal
cancer. Two children were diagnosed with colorectal cancer at very early ages (13
and 7). The parents of the 13 year old girl were first cousins in a consanguineous
marriage. Both father and mother tested heterozygous for the A1652C mutation, as
did two of their three children tested. There is a 25% probability that the 13 year old
daughter could have inherited a mutant allele from each parent and have been
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homozygous for the mutation. The resulting MLHl-deficiency might have caused her 
to die at such an early age. This phenomenon has been previously observed in another 
Turkish HNPCC kindred (manuscript submitted, Ricciardone et al.).
Some of these restriction enzyme results were confirmed for several 
individuals by sequencing. There was one discrepancy: individual 97-184 was 
determined to be heterozygous by both Hph\ restriction enzyme analysis and DNA 
sequence analysis at Bilkent, but wild-type by DNA sequence analysis in France 
(Wang et al., 1997). Isolation of DNA from a different sample aliquot, followed by 
HphI restriction enzyme analysis and DNA sequence analysis gave the same results.
In order to eliminate any suspicion of sample mix-up, a new blood sample must be 
obtained from this individual and tested before any genetic counseling can be given.
This A1652C missense mutation results in a Asn->Thr substitution, whose 
effect on MLHl structure and function is unknown. However, since no A1652C 
transversion was found in 50 unrelated individuals from Turkish population (Wang et 
al., 1997), this, too, is a probably pathogenic mutation and not simply a 
polymorphism. Asparagine and threonine are both hydrophilic amino acids with 
uncharged side chains. Asparagine 551 is a potential site (underlined in Figure 4) for 
glycosylation, a post-translational chemical modification needed for proper folding. 
Loss of this site might result in a change of protein structure and function.
In the HNPCC 5 family, hMLHI exons 15 and 7 showed a difference in 
migration between the proband and control samples by SSCP analysis. All the other 
exons were negative by SSCP analysis. In order to determine the cause of this 
differential mobility DNA sequence analysis was performed. No mutation was 
observed in the coding sequence of exon 15. However, an intronic polymorphism
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was detected in the control DNA samples and this polymorphism most likely accounts 
for the SSCP differential mobility.
Preliminaiy DNA sequence analysis of exon 7 suggests that there is no 
nucleotide change within the region analyzed. The antisense sequence must be 
obtained using the reverse primer in order to confirm these preliminary results. If a 
sequence change is found in the coding region of this exon, further studies should be 
done on other family members to demonstrate that the mutation cosegregates with the 
disease. Other analyses must be done to determine whether the alteration is a 
pathogenic mutation or a polymorphism. The nature of the mutation will give some 
clues. Nonsense mutations and frameshift mutations are usually pathogenic, whereas 
missense mutations are often polymorphisms.
If there is no mutation in the coding sequence of exon 7, then there appears to 
be no germline hMLHI mutation. However, this conclusion must be tempered by the 
knowledge that the SSCP protocols that have been used were not capable of detecting 
all mutations. The three SSCP protocols that were used in this analysis were capable 
of detecting only seven out of nine (-80%) known mutations.
In order to rule out an hMLHI mutation, the remaining exons should be 
examined by DNA sequence analysis. If no mutation is found in the hMLHI DNA 
sequence, then one of the other mismatch repair genes may be defective. The most 
obvious candidate would be hMSH2 because germline mutations in this gene have 
been identified in a high proportion of HNPCC families.
Samples from the HNPCC 3 and HNPCC 4 individuals were used as controls
in the SSCP analysis because the mutations responsible for HNPCC were previously
defined. These two mutations do not destroy or add a restriction enzyme recognition
site, so restriction enzyme analysis is not a feasible low-cost screening method for
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these families. However, now that these mutations have been detected by SSCP, 
other family members can be screened using this assay rather than DNA sequence 
analysis.
Perspectives
In order to fully characterize the spectnam of mutations in the Turkish 
population, more HNPCC families must be screened. Based on the results presented 
here, a mutation screening protocol for Turkish kindreds might include: (1) I)tk\ 
restriction enzyme analysis for the G884C mutation; (2) Hph\ restriction enzyme 
analysis for the A1652C mutation; (3) protein truncation test for the C676T mutation 
and other nonsense mutations; (4) SSCP analysis using protocols 1, 2, and 7; and 
finally (5) DNA sequence analysis. Restriction enzyme analysis is efficient and 
inexpensive. SSCP is a valuable screening method but under optimal conditions 
sensitivity is only 80% (Cotton, 1997). DNA sequence analysis must be used to 
confirm a DNA mutation that is suggested by differential mobility with SSCP.
More sensitive mutation screening tests e.g. fluorescent assisted mismatch 
cleavage analysis (FAMA) need to be developed. In this technique, sense and 
antisense strands are simultaneously labeled with strand-specific fluorochromes during 
PCR amplification. Heteroduplexes are allowed to form between wild-type and 
mutant sequences. Mismatches are cleaved using chemicals or enzymes and the 
cleaved products are then analyzed and sized on the automated ABI 377 DNA 
Sequencer using GeneScan software. The main advantages of FAM A are its ability to 
detect 100% of mutations and to provide accurate positional information. Its ability 
to screen 1-2 kb lengths of DNA is a significant advantage over DNA sequencing.
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Although the missense mutations so far discovered in Turkish HNPCC 
individuals appear to be pathogenic, a test that could assay the eificiency of mismatch 
repair by in wild-type and mutant proteins would be useful in determining whether a 
particular mutation was deleterious or merely a polymorphism. For this assay, 
colorectal cancer cell lines can be used as controls and +/+, +/- and -/- cell lines can be 
tested for their ability to repair DNA substrates containing different mismatches 
(Edelmann et al., 1997).
Additional studies to determine the downstream consequences of these 
mismatch repair gene mutations also need to be done. Tumors isolated from HNPCC 
individuals have been found to have mutations in mononucleotide tracts within several 
growth regulating genes (Markowitz et al., 1995; Souza et al,, 1996; Rampino et al.,
1997). Genetic analysis of tumors from these HNPCC individuals might yield further 
clues about other events required for the development of colorectal cancers.
While some of the studies mentioned above are long-term projects, an 
immediate effect of this study is the availability of relatively simple, cost-effective and 
reliable diagnostic tests that can be used to assess a number of germline mutations 
responsible for HNPCC in Turkish kindreds. Presymptomatic screening of germline 
mutations in DNA mismatch repair genes is clearly warranted for these family 
members. In addition, these family members must receive genetic counseling that is 
compassionate, empathetic and combined with appropriate education. Special care 
must be given to patients’ culture, beliefs and traditions.
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